

**CUMULATIVE
SUPPLEMENT 10**


JAN'94-OCT'94

APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

14TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES



RM
301.45
.A66
1994
Oct
Suppl

Library Use Only

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

Library Use Only

SUBSCRIBE NOW!

Available in March 1995

New 15th Edition



**APPROVED
DRUG PRODUCTS**

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

**15TH EDITION
1995**

CONTENTS

- Prescription/Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

RM301.45 .A66 1994 Oct Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

14TH EDITION

Cumulative Supplement 10

OCTOBER 1994

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Products Requiring Revised Labeling for Full Approval	v
1.3 Applicant Name Changes	vi
1.4 New Indications for Previously Approved Drug Products	vii
1.5 USP Monograph Title Additions or Changes	viii
1.6 Report of Counts for the Prescription Drug Product List	x
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	51
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	53
2.4 Orphan Drug Product Designations	54
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	59
2.6 Biopharmaceutic Guidance Availability	60
2.7 ANDA Suitability Petitions	61
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Exclusivity Terms	63
B. Patent and Exclusivity Lists	64

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

14TH EDITION

CUMULATIVE SUPPLEMENT 10

OCTOBER 1994

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 14th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing shaded print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 14th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 15th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

<u>Products</u>	<u>Federal Register Reference</u>
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ADRIA LABORATORIES DIV ERBAMONT INC (ADRIA)	PHARMACIA INC (PHARMACIA)
BANNER GELATIN PRODUCTS CORP (BANNER GELATIN)	BANNER PHARMACAPS INC (BANNER PHARMACAPS)
CLONMEL CHEMICALS CO LTD (CLONMEL)	CLONMEL HEALTHCARE LIMITED (CLONMEL)
DUPONT PHARMACEUTICALS (DUPONT)	DUPONT MERCK PHARMACEUTICALS CO (DUPONT MERCK)
GYNEX INC (GYNEX)	BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP (BTG PHARMS)
KABI PHARMACIA INC (KABI)	PHARMACIA INC (PHARMACIA)
MALLINCKRODT SPECIALTY CHEMICALS CO (MALLINCKRODT)	MALLINCKRODT CHEMICAL INC (MALLINCKRODT)
NORTH AMERICAN CHEMICAL CORP (NORTH AM CHEM)	GOLDEN PHARMACEUTICALS INC (GOLDEN PHARM)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

PHARMACEUTICAL BASICS INC
(PHARM BASICS)

ROSEMONT PHARMACEUTICAL CORPORATION
(ROSEMONT PHARM)

RICHLYN LABORATORIES INC
(RICHLYN)

GLOBAL PHARMACEUTICAL CORPORATION
(GLOBAL PHARM)

SQUIBB DIAGNOSTICS
(SQUIBB)

BRACCO DIAGNOSTICS INC
(BRACCO)

1.4 NEW INDICATIONS FOR PREVIOUSLY APPROVED DRUG PRODUCTS

When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by the same firm, the application is either submitted as a supplement to the original NDA (if the clinical expertise for the review of the new indication resides in the same division that reviewed the original NDA), or as a "Type 6 NDA" and assigned a new NDA number (if the clinical expertise for the review of the new indication resides in another review division). When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by a different firm, the application is classified as "Type 6" and assigned a new NDA number. For administrative purposes, FDA has been listing all "Type 6 NDA's" in the *Approved Drug Products with Therapeutic Equivalence Evaluations*, (ADP), even when the application was submitted by the original NDA holder. However, FDA has determined that the practice of listing a separate "Type 6 NDA" number in the ADP when the applicant is the original NDA holder may cause confusion to the ADP reader.

Accordingly, to prevent confusion and to eliminate duplicity of data, the approval of an application for a new indication for a previously approved drug product submitted by the original NDA holder will no longer be listed in the ADP. Any exclusivity awarded for that approval will be shown in the Patent and Exclusivity Information Addendum under the original NDA number. However, approval of an application for a new indication submitted by an applicant other than the original NDA holder will be shown in the appropriate drug product list of the ADP. Any exclusivity awarded will be shown under the NDA number of the new applicant.

All approvals of "Type 6" applications submitted by the original NDA holder currently in the ADP are listed in the table below. For reference purposes, the original NDA number is listed next to the corresponding "Type 6 NDA Number". This data ("Type 6 NDA Number") will continue to be listed in the remaining Cumulative Supplements to the 14th Edition of the ADP; but it will not appear in the 15th Edition of the ADP.

<u>TYPE 6 NDA NUMBER</u>	<u>ORIGINAL NDA NUMBER</u>	<u>ACTIVE INGREDIENT (TRADE NAME)</u>	<u>DOSAGE FORM (ROUTE)</u>
17-117	16-020	AMANTADINE HCL (SYMMETREL)	CAPSULE (ORAL)
17-118	16-023	AMANTADINE HCL (SYMMETREL)	SYRUP (ORAL)
50-697	50-662	CLARITHROMYCIN (BIAxin)	TABLET (ORAL)
19-576	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
19-648	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
18-064	18-063	NADOLOL (CORGARD)	TABLET (ORAL)
20-109	19-886	NAFARELIN ACETATE (SYNAREL)	SPRAY, METERED (NASAL)
20-223	19-057	TERAZOSIN HCL (HYTRIN)	TABLET (ORAL)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE
(FORMER ADP DOSAGE FORM; ROUTE)

NEW USP MONOGRAPH TITLE
(NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF OCTOBER 1994.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1993) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1993</u>	<u>MAR 1994</u>	<u>JUN 1994</u>	<u>SEP 1994</u>
DRUG PRODUCTS LISTED	9140	9153	9079	9092
SINGLE SOURCE	2144 (23.5%)	2151 (23.5%)	2150 (23.7%)	2127 (23.4%)
MULTISOURCE	6996 (76.5%)	7002 (76.5%)	6929 (76.3%)	6965 (76.6%)
THERAPEUTICALLY EQUIVALENT	6292 (68.8%)	6306 (68.9%)	6290 (69.3%)	6329 (69.6%)
NOT THERAPEUTICALLY EQUIVALENT	527 (5.8%)	513 (5.6%)	458 (5.0%)	453 (5.0%)
EXCEPTIONS ¹	177 (1.9%)	183 (2.0%)	181 (2.0%)	183 (2.0%)
NEW MOLECULAR ENTITIES APPROVED	--	6	5	2
NUMBER OF APPLICANTS	526	528	490	539

¹Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

PRESCRIPTION DRUG PRODUCT LIST

14TH EDITION
RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'94 - OCT'94

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

MEDIGESIC PLUS
US CHEM

325MG; 50MG; 40MG

N89115 001
JAN 14, 1986

325MG; 50MG; 40MG

N89115 001
JAN 14, 1986

@

> ADD >
> ADD >

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB 2%, 1%

N40097 001
OCT 31, 1994

ACETYLCHOLINE CHLORIDE

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

COMPAL

PURDUE FREDERICK

356.4MG; 30MG; 16MG

N88584 001
MAR 04, 1986

DHC PLUS

PURDUE FREDERICK

356.4MG; 30MG; 16MG

N88584 001
MAR 04, 1986> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

POWDER FOR RECONSTITUTION; OPHTHALMIC

MIOCHOL

+ CIBA VISION

* IOLAB 20MG/VIAL

MIOCHOL-E 20MG/VIAL

+ CIBA VISION

* IOLAB 20MG/VIAL

20MG/VIAL

N16211 001
N16211 001
N20213 001
SEP 22, 1993
N20213 001
SEP 22, 1993

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

CO-GESIC
CENT PHARMS

500MG; 5MG

N89360 001
MAR 02, 1988

500MG; 5MG

N89360 001
MAR 02, 1988

@

> ADD >
> DLT >
> ADD >
> DLT >
> ADD >
> DLT >

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

ABBOTT

AN 10%

AN 20%

N73664 001
AUG 30, 1994
N74037 001
AUG 30, 1994

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

BAUSCH AND LOMB 2%; 0.79%

N40063 001
FEB 25, 1994

BOROFAIR

PHARMAPAIR

2%; 0.79%

N88606 001
AUG 21, 1985

2%; 0.79%

N88606 001
AUG 21, 1985

@

DOMEORO

MILES

2%; 0.79%

N84476 001
N84476 001

+

> ADD >
> DLT >
> ADD >
> DLT >
> ADD >
> DLT >

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+ BURROUGHS WELLCOME 8MG; 60MG

N19806 001
MAR 25, 1994

ALBUTEROL SULFATE

SYRUP; ORAL

ALBUTEROL SULFATE

MOVA

EQ 2MG BASE/5ML

N74302 001
SEP 30, 1994

TABLET; ORAL

ALBUTEROL SULFATE

WARNER CHILCOTT

EQ 2MG BASE

N72817 001
JAN 09, 1990

ALBUTEROL SULFATE

TABLET; ORAL
ALBUTEROL SULFATE
 WARNER CHILCOTT

AB EQ 4MG BASE
 @
 EQ 2MG BASE
 @
 EQ 4MG BASE

N72818 001
 JAN 09, 1990
 N72817 001
 JAN 09, 1990
 N72818 001
 JAN 09, 1990

AMBENONIUM CHLORIDE

TABLET; ORAL
 MYTELASE
 SANOFI WINTHROP
 STERLING WINTHROP

10MG
 10MG

N10155 002
 N10155 002

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN
 ABBOTT

AP EQ 250MG BASE/ML
 > ADD >
 > DLT >
 > ADD >
 > ADD >
 > ADD >

N63266 001
 OCT 31, 1994
 N63283 001
 OCT 31, 1994
 N63313 001
 APR 11, 1994
 N63315 001
 APR 11, 1994
 N63274 001
 MAY 18, 1992
 N63274 001
 MAY 18, 1992
 N63275 001
 MAY 18, 1992
 N63275 001
 MAY 18, 1992

0.25MG

0.5MG

1MG

2MG

0.25MG

0.5MG

1MG

0.25MG

0.5MG

1MG

2MG

N74215 001
 JAN 27, 1994
 N74215 002
 JAN 27, 1994
 N74215 003
 JAN 27, 1994
 N74215 004
 JAN 27, 1994
 N74085 001
 FEB 16, 1994
 N74085 002
 FEB 16, 1994
 N74085 003
 FEB 16, 1994
 N74294 001
 JUL 29, 1994
 N74294 002
 JUL 29, 1994
 N74294 003
 JUL 29, 1994
 N74294 004
 JUL 29, 1994

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
 MYLAN

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AB

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
 HI TECH PHARMA

50MG/5ML

N74170 001
 OCT 28, 1994

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
 AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT

N19565 001
 DEC 17, 1986

AMITRIPTYLINE HYDROCHLORIDE

TABLET: ORAL

AMIKACIN	10MG
25MG	
50MG	
75MG	
100MG	
150MG	

100MG
150MG

AMOXICILLIN

<u>AMOXICILLIN</u>	
CAPSULE; ORAL	
<u>AB</u>	<u>AMOXICILLIN</u> <u>BIOCHEMIE</u> <u>250MG</u>
AB	500MG

AB	BIOCHEMIE	250MG
AB		500MG

AB **POLYMOX**
APOTHECON

AB	250MG	APOTHECON
AB	500MG	
AB	250MG	BRISTOL MYERS
AB	500MG	

POWDER FOR RECONSTITUTION; ORAL

AB	<u>POLYMAX</u>	125MG/5ML
AB	@ APOTHECON	125MG/5ML
AB	@	250MG/5ML
AB	@	250MG/5ML
AB	@	125MG/5ML
AB	<u>BRISTOL</u>	125MG/5ML
AB		250MG/5ML
AB		250MG/5ML

AMPHETAMINE SULFATE

TABLET; ORAL
AMPHETAMINE SULFATE
LANNETT
5MG

AMPHETAMINE SULFATE
LANNETT
5MG

AMPHETAMINE SULFATE

TABLET, ORAL
AMPHETAMINE SULFATE
LANNETT

10MG

5MG

10MG

N83901 002
AUG 31, 1984
N83901 001
AUG 31, 1984
N83901 002
AUG 31, 1984

> DLT >
> DLT >

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A

0.5%; 0.05%

N18746 001
APR 30, 1990

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE
HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

FUJISAWA

50MG/VIAL

50MG/VIAL

N62728 001
APR 13, 1987
N62728 001
APR 13, 1987

INJECTABLE; INJECTION

M.V.C. 9+3
FUJISAWA

10MG/ML; 0.006MG/ML; 0.5 UGM/ML;
1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML;
0.4MG/ML; 0.36MG/ML; 0.3MG/ML;
330 UNITS/ML; 1 IU/ML
N18440 002
AUG 08, 1985

10MG/ML; 0.006MG/ML; 0.5 UGM/ML;
1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML;
0.4MG/ML; 0.36MG/ML; 0.3MG/ML;
330 UNITS/ML; 1 IU/ML
N18440 002
AUG 08, 1985

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

POLYICILLIN

@ APOTHECON

BRISTOL

EQ 125MG BASE/5ML
EQ 250MG BASE/5ML
EQ 125MG BASE/5ML
EQ 250MG BASE/5ML

N62297 001
N62297 002
N62297 001
N62297 002

ATENOLOL

TABLET; ORAL

ATENOLOL
GENPHARM

50MG

100MG

25MG

50MG

100MG

N74126 001
MAR 23, 1994
N74126 002
MAR 23, 1994
N74265 001
FEB 28, 1994
N74265 002
FEB 28, 1994
N74265 003
FEB 28, 1994

> ADD >
> ADD >
> DLT >
> DLT >

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+ CIBA VISION

0.5%; 0.05%

N18746 001
APR 30, 1990

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

LOFENE

LANNETT

0.025MG; 2.5MG
0.025MG; 2.5MG

N85372 001
N85372 001

> ADD >
> ADD >

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'94 - OCT'94

AZITHROMYCIN DIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

ZITHROMAX

+ PFIZER

EQ 1GM BASE/PACKET

N50693 001
SEP 28, 1994

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATEAB BETAMETHASONE DIPROPIONATE

EQ 0.05% BASE

N74272 001
SEP 30, 1994BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

AT PHARMACEUTICALSAT PHARMACEUTICALS

500 UNITS/GM

500 UNITS/GM

500 UNITS/GM

500 UNITS/GM

N62158 001

N62158 001

N62453 001

MAR 28, 1984

N62453 001

MAR 28, 1984

BACLOFEN

TABLET; ORAL

BACLOFEN

AB ROYCE LABS

10MG

N73092 001

JAN 28, 1994

N73093 001

JAN 28, 1994

20MG

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

* LANNETT

@

50%

50%

N84535 001

N84535 001

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

DIPROLENE

* SCHERING

@

EQ 0.05% BASE

N19408 001

JAN 31, 1986

N19408 001

JAN 31, 1986

EQ 0.05% BASE

GEL; TOPICAL

DIPROLENE

+ SCHERING

EQ 0.05% BASE

N19408 002

NOV 22, 1991

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATEAB BETAMETHASONE DIPROPIONATE

EQ 0.05% BASE

N74272 001
SEP 30, 1994

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATEAB BETAMETHASONE DIPROPIONATE

EQ 0.05% BASE

N74271 001
SEP 15, 1994BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATEAB PHARMACEUTICALS

EQ 0.1% BASE

N70484 001
MAY 29, 1987

N70484 001

MAY 29, 1987

> DLT >

> DLT >

> ADD >

> ADD >

OINTMENT; TOPICAL

BETAMETHASONE VALERATEB CLAY PARK

EQ 0.1% BASE

N71478 001
DEC 23, 1987

N71478 001

DEC 23, 1987

EQ 0.1% BASE

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDEAA LANNETTAA LANNETTAA LANNETT

5MG

10MG

25MG

5MG

10MG

25MG

N84702 001

N84712 001

N84074 001

N84702 001

N84712 001

N84074 001

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

+ SANOFI WINTHROP

0.37MG/INH

N18770 001
DEC 28, 1984

> ADD >

> ADD >

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE
* STERLING WINTHROP 0.37MG/INH

> DLT >
> DLT >

N18770 001
DEC 28, 1984

SOLUTION; INHALATION

TORNALATE
SANOFI WINTHROP 0.2%

> ADD >
> ADD >

N19548 001
FEB 19, 1992

STERLING WINTHROP 0.2%

> DLT >
> DLT >

N19548 001
FEB 19, 1992

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE;

PSEUDOPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DX

ROBINS AH

AA

2MG/5ML; 10MG/5ML; 30MG/5ML N11694 007
MAR 29, 1984

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

+ ASTRA

0.05MG/INH

N20233 001
FEB 14, 1994

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP SANOFI WINTHROP

0.25MG/ML

N74332 001
OCT 31, 1994

BUMEX

AP + ROCHE

0.25MG/ML

N18226 001
FEB 28, 1983

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTALAN

LANNETT

@

33.3MG/5ML
33.3MG/5ML

N85880 001
N85880 001

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

AA WALLACE

100MG
100MG

N00793 005
N00793 005

SODIUM BUTABARBITAL

AA LANNETT

100MG
100MG

N85881 001
N85881 001

AA ZENITH

30MG
30MG

N84040 001
N84040 001

@ ZENITH LABS

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

BR G AND W LABS

100MG; 2MG

N86557 001
OCT 04, 1983

WIGRAINE

BR ORGANON

100MG; 2MG

N86557 001
OCT 04, 1983

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON

0.02MG
0.05MG

N18312 001
N18312 002

+

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL

CALDEROL

ORGANON

0.02MG
0.05MG

N18312 001
N18312 002

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELPLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN

PLASTIC CONTAINER

FRESENIUS

18.4MG/100ML; 1.5GM/100ML;
5.08MG/100ML; 538MG/100ML;
448MG/100ML

N20171 001
AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN
PLASTIC CONTAINER
 AT FRESNIUS 18.4MG/100ML; 2.5GM/100ML; N20171 002
 5.08MG/100ML; 538MG/100ML; AUG 19, 1992
 448MG/100ML
 DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN
 PLASTIC CONTAINER
 AT FRESNIUS 18.4MG/100ML; 4.25GM/100ML; N20171 003
 5.08MG/100ML; 538MG/100ML; AUG 19, 1992
 448MG/100ML
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 AT BAXTER 18.3MG/100ML; 1.5GM/100ML; N20183 001
 5.08MG/100ML; 538MG/100ML; DEC 04, 1992
 448MG/100ML
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 AT BAXTER 18.3MG/100ML; 2.5GM/100ML; N20183 002
 5.08MG/100ML; 538MG/100ML; DEC 04, 1992
 448MG/100ML
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
 AT BAXTER 18.3MG/100ML; 3.5GM/100ML; N20183 003
 5.08MG/100ML; 538MG/100ML; DEC 04, 1992
 448MG/100ML
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
 AT BAXTER 18.3MG/100ML; 4.25GM/100ML; N20183 004
 5.08MG/100ML; 538MG/100ML; DEC 04, 1992
 448MG/100ML
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 AT BAXTER 18.3MG/100ML; 1.5GM/100ML; N17512 004
 5.08MG/100ML; 538MG/100ML; N17512 004
 448MG/100ML
 INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
 AT ABBOTT 18.4MG/100ML; 1.5GM/100ML; N20374 001
 5.08MG/100ML; 538MG/100ML; JUN 13, 1994
 448MG/100ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE;
SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
 AT ABBOTT 18.4MG/100ML; 2.5GM/100ML; N20374 002
 5.08MG/100ML; 538MG/100ML; JUN 13, 1994
 448MG/100ML
 INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
 AT ABBOTT 18.4MG/100ML; 3.5GM/100ML; N20374 003
 5.08MG/100ML; 538MG/100ML; JUN 13, 1994
 448MG/100ML
 INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
 AT ABBOTT 18.4MG/100ML; 4.25GM/100ML; N20374 004
 5.08MG/100ML; 538MG/100ML; JUN 13, 1994
 448MG/100ML
 CARBACHOL
 INJECTABLE; INJECTION
 CARBACHOL 0.01% N70292 001
 @ PHARMAFAIR MAY 21, 1986
 MIOTAT 0.01% N16968 001
 * ALCON
 SOLUTION; INTRAOCULAR
 CARBACHOL 0.01% N70292 001
 @ PHARMAFAIR MAY 21, 1986
 MIOTAT 0.01% N16968 001
 + ALCON
 CARBAMAZEPINE
 SUSPENSION; ORAL
 TEGRETOL 100MG/5ML N18927 001
 + BASEL PHARMS DEC 18, 1987
 * GEIGY 100MG/5ML N18927 001
 DEC 18, 1987
 TABLET; ORAL
 TEGRETOL 200MG N16608 001
 AB + BASEL PHARMS

CARBAMAZEPINE

TABLET; ORAL

TEGRETOLAB * GEIGY 200MG

TABLET, CHEWABLE; ORAL

TEGRETOLAB + BASEL PHARMSAB * GEIGY 100MG
100MGCARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPAAB SCS10MG; 100MGAB25MG; 100MGAB25MG; 250MG

TABLET, EXTENDED RELEASE; ORAL

SINEMET CRMERCK SHARP DOHME 25MG; 100MGCEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXILAB APOTHECONAB ZENITH LABSEQ 500MG BASEEQ 500MG BASE

⊙

EQ 500MG BASEULTRACEFAB BRISTOLEQ 500MG BASE

POWDER FOR RECONSTITUTION; ORAL

CEFADROXILAB APOTHECONAB APOTHECONAB APOTHECONAB APOTHECONEQ 125MG BASE/5MLEQ 250MG BASE/5MLEQ 500MG BASE/5MLEQ 125MG BASE/5MLEQ 250MG BASE/5MLULTRACEFAB BRISTOLAB BRISTOLAB BRISTOLCEFADROXIL/CEFADROXIL HEMIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

ULTRACEFAB BRISTOLEQ 500MG BASE/5ML

TABLET; ORAL

CEFADROXILAB ZENITH LABSEQ 1GM BASEEQ 1GM BASE

⊙

ULTRACEFAB APOTHECONEQ 1GM BASEAB BRISTOLEQ 1GM BASECEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUMAP FUJISAWAEQ 500MG BASE/VIALAPEQ 1GM BASE/VIALAPEQ 10GM BASE/VIALAPEQ 20GM BASE/VIAL

⊙

EQ 500MG BASE/VIAL

⊙

EQ 1GM BASE/VIAL

⊙

EQ 10GM BASE/VIAL

⊙

EQ 20GM BASE/VIALCEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOXAB FUJISAWAEQ 1GM BASE/VIALEQ 2GM BASE/VIAL

N62394 002

MAR 31, 1994

N62394 003

MAR 31, 1994

N62334 003

N62774 001

APR 08, 1987

N62774 001

APR 08, 1987

N62390 001

JUN 10, 1982

N62390 001

JUN 10, 1982

N62688 002

NOV 17, 1986

N62688 003

NOV 17, 1986

N62688 004

NOV 17, 1986

N62688 005

AUG 03, 1987

N62688 002

NOV 17, 1986

N62688 003

NOV 17, 1986

N62688 004

NOV 17, 1986

N62688 005

AUG 03, 1987

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'94 - OCT'94

9

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL
CEFTIN
+ GLAXO

N50672 001
JUN 30, 1994

N62437 001
APR 14, 1983

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

SEFFIN
GLAXO

EQ 1GM BASE/VIAL

N62435 001
NOV 15, 1983

EQ 2GM BASE/VIAL

N62435 002
NOV 15, 1983

EQ 10GM BASE/VIAL

N62435 003
NOV 15, 1983

EQ 1GM BASE/VIAL

N62435 001
NOV 15, 1983

EQ 2GM BASE/VIAL

N62435 002
NOV 15, 1983

EQ 10GM BASE/VIAL

N62435 003
NOV 15, 1983

CHENODIOL

TABLET; ORAL

CHENIX
+ SOLVAY

250MG

N18513 002
JUL 28, 1983

250MG

N18513 002
JUL 28, 1983

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC

CHLOROPAIR
PHARMAFAIR

1%

N62439 001
APR 21, 1983

1%

N62439 001
APR 21, 1983

SOLUTION/DROPS; OPHTHALMIC

CHLOROPAIR
PHARMAFAIR

0.5%

N62437 001
APR 14, 1983

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC

CHLOROPAIR
@ PHARMAFAIR

0.5%

N62437 001
APR 14, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIDEX

AT + PROCTER AND GAMBLE 0.12%

N19028 001
AUG 13, 1986

PERIOGARD

AT COLGATE PALMOLIVE 0.12%

N73695 001
JAN 14, 1994

CHLORMERODRIN, HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

@ BRACCO DXS

@ SQUIBB

N17269 001
N17269 001

0.6-1.4mCi/ML
0.6-1.4mCi/ML

CHLORMEZANONE

TABLET; ORAL

TRANSCOPAL

SANOFI WINTHROP

100MG

N11467 003

200MG

N11467 005

100MG

N11467 003

200MG

N11467 005

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HCL

+ SANOFI WINTHROP

* STERLING WINTHROP

EQ 40MG BASE/ML

N06002 002

EQ 40MG BASE/ML

N06002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

SANOFI WINTHROP

EQ 300MG BASE

N06002 001

> ADD > AA

> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

> ADD >
> ADD >
> DLT >
> DLT >

> ADD >
> DLT >

> ADD > AA

CHLOROQUINE PHOSPHATE

TABLET; ORAL

> DLT >
AA ARALEN
STERLING WINTHROP EQ 300MG BASE

N06002 001
 > DLT >
 > DLT >

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

CATAPASE
 @ IO LAB *
150 UNITS/VIAL
300 UNITS/VIAL

N18121 001
N16938 001

CHLOROQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

TABLET; ORAL

> ADD >
 > ADD >
 > DLT >
 > DLT >

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
 @ SANOFI WINTHROP EQ 300MG BASE;
 EQ 45MG BASE
 @ STERLING WINTHROP
EQ 100MG BASE
EQ 45MG BASE

N14860 002
N14860 002
 200MG
 300MG
 400MG
 800MG

N74281 001
 MAY 17, 1994
N74281 002
 MAY 17, 1994
N74281 003
 MAY 17, 1994
N74329 001
 MAY 17, 1994
N74246 001
 MAY 17, 1994
N74246 002
 MAY 17, 1994
N74246 003
 MAY 17, 1994
N74246 004
 MAY 17, 1994
N74151 001
 MAY 17, 1994
N74151 002
 MAY 17, 1994
N74151 003
 MAY 17, 1994
N74463 001
 MAY 17, 1994

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

AA CHLORPHENIRAMINE MALEATE
ZENITH 4MG
 @ ZENITH LABS 4MG

N80779 001
N80779 001

CHLORTHALIDONE

TABLET; ORAL

THALITONE
 HORUS THERAP 15MG
 15MG
 +

N19574 001
 DEC 20, 1988
N19574 001
 DEC 20, 1988

CHOLESTYRAMINE

TABLET; ORAL

QUESTRAN
 + BRISTOL MYERS SQUIBB EQ 1GM RESIN

N73403 001
 APR 28, 1994

TAGAMET

SMITHKLINE BEECHAM

AB
AB
AB

200MG
 300MG
 400MG

N17920 002
N17920 003
N17920 004
 DEC 14, 1983
N17920 005
 APR 30, 1986

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

CATAPASE
 @ CIBA VISION
 150 UNITS/VIAL
 300 UNITS/VIAL
 +

> ADD >
 > ADD >

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

AP ENDO LABS

EQ 300MG BASE/2ML

N74005 001
AUG 31, 1994

AP TAGAMET
+ SMITHKLINE BEECHAM

EQ 300MG BASE/2ML

N17939 002

SOLUTION; ORAL

CIMETIDINE HCL

AA BARRE

EQ 300MG BASE/5ML

N74176 001
JUN 01, 1994

AA TAGAMET
SMITHKLINE BEECHAM

EQ 300MG BASE/5ML

N17924 001

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA LEMMON

EQ 0.5MG BASE/5ML

N73399 001
JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP BEDFORD

EQ 150MG BASE/ML

N63163 001
JUN 30, 1994

AP DUPONT

EQ 150MG BASE/ML

N62908 001
FEB 01, 1989

@ DUPONT MERCK

EQ 150MG BASE/ML

N62908 001
FEB 01, 1989

AP FUJISAWA

EQ 150MG BASE/ML

N62747 001
JUN 03, 1988

@

EQ 150MG BASE/ML

N62747 001
JUN 03, 1988

SOLUTION; TOPICAL

CLEOCIN

UPJOHN

EQ 1% BASE

N50537 002
FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB COPLEY PHARM

0.05%

N74087 001
FEB 16, 1994

AB NMC

0.05%

N74139 001
AUG 03, 1994

AB TEMOVATE
+ GLAXO

0.05%

N19322 001
DEC 27, 1985

AB *

0.05%

N20340 001
JUN 17, 1994

TEMOVATE EMOLLIENT

0.05%

N20340 001
JUN 17, 1994

GEL; TOPICAL

TEMOVATE

+ GLAXO

0.05%

N20337 001
APR 29, 1994

ointment; TOPICAL

CLOBETASOL PROPIONATE

AB COPLEY PHARM

0.05%

N74089 001
FEB 16, 1994

AB NMC

0.05%

N74128 001
AUG 03, 1994

AB TEMOVATE
+ GLAXO

0.05%

N19323 001
DEC 27, 1985

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

BASEL PHARMS

25MG

N19906 001
DEC 29, 1989

50MG

N19906 002
DEC 29, 1989

75MG

N19906 003
DEC 29, 1989

25MG

N19906 001
DEC 29, 1989

50MG

N19906 002
DEC 29, 1989

75MG

N19906 003
DEC 29, 1989

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE
HYDROCHLORIDE

SYRUP; ORAL
AA PROMETHAZINE VC W/ CODEINE
 PENNEX 10MG/5ML; 5MG/5ML;
 6.25MG/5ML N88896 001
 JAN 04, 1985
 @ PENNEX PHARMS 10MG/5ML; 5MG/5ML;
 6.25MG/5ML N88896 001
 JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
AA PROMETHAZINE W/ CODEINE
 PENNEX 10MG/5ML; 6.25MG/5ML N88875 001
 DEC 17, 1984
 @ PENNEX PHARMS 10MG/5ML; 6.25MG/5ML N88875 001
 DEC 17, 1984

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
 COLESTID 1GM N20222 001
 UPJOHN JUL 19, 1994

CORTISONE ACETATE

INJECTABLE; INJECTION
 CORTISONE ACETATE
 STERIS

BP 25MG/ML N83147 003
 BP 25MG/ML N83677 001
 BP 50MG/ML N83147 004
 BP 50MG/ML N85677 002
 @ 25MG/ML N83147 003
 @ 25MG/ML N85677 001
 @ 50MG/ML N83147 004
 @ 50MG/ML N85677 002
 @ 25MG/ML N88126 002
 @ 25MG/ML N08126 002
 CORTONE 25MG/ML N07110 002
 MERCK SHARP DOHME 50MG/ML N07110 003
 + MSD 25MG/ML N07110 002

CORTISONE ACETATE

INJECTABLE; INJECTION
 CORTONE
 BP * MSD 50MG/ML N07110 003

TABLET; ORAL
 CORTISONE ACETATE
 BP INWOOD 25MG N80731 001
 @ INWOOD LABS 25MG N80731 001

CROMOLYN SODIUM

SOLUTION; INHALATION
 CROMOLYN SODIUM
 AN DEV 10MG/ML N74209 001
 APR 26, 1994

AN INTAL 10MG/ML N18596 001
 + FISONS MAY 28, 1982

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL
 RUBRATOPE-57
 BRACCO DXS 0.5-1 uCi N16089 002
 SQUIBB 0.5-1 uCi N16089 002

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL
 RUBRATOPE-60
 @ BRACCO DXS 0.5-1 uCi N16090 002
 @ SQUIBB 0.5-1 uCi N16090 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
 CYCLOGYL
 AT * ALCON 0.5% N84109 001
 + 0.5% N84109 001

AT PENTOLAIR 1% N40075 001
 BAUSCH AND LOMB APR 29, 1994

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PENTOLAIRAT PHARMFAIR 0.5%

FEB 09, 1987

N88643 001

AT 1%

FEB 25, 1983

N88150 001

@ 0.5%

FEB 09, 1987

N88643 001

@ 1%

FEB 25, 1983

N88150 001

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCLAA CHELSEA 4MG

FEB 25, 1983

N86165 001

@ CHELSEA LABS 4MG

FEB 25, 1983

N86165 001

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGONMYLAN

EQ 50MG BASE

AUG 15, 1994

N20392 001

EQ 150MG BASE

AUG 15, 1994

N20392 002

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE+ BULL D

20MG/ML

FEB 28, 1994

N72945 001

AP CETUS BEN VENUE1GM/VIAL

AUG 31, 1994

N74245 001

AP 2GM/VIAL

AUG 31, 1994

N74245 002

CYTOSAR-U+ UPJOHN1GM/VIAL

DEC 21, 1987

N16793 003

AP 2GM/VIAL

DEC 21, 1987

N16793 004

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN+ MERCK SHARP DOHME* MSD

0.5MG/VIAL

0.5MG/VIAL

N50682 001

N60467 001

DANAZOL

CAPSULE; ORAL

DANOCRINESANOFI WINTHROP

50MG

100MG

200MG

50MG

100MG

200MG

N17557 003

N17557 004

N17557 002

N17557 003

N17557 004

N17557 004

N17557 002

+ STERLING WINTHROP* MSD

0.15MG/INH

0.15MG/INH

N20355 001

MAR 07, 1994

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE+ RHONE POULENC RORER

0.15MG/INH

0.15MG/INH

N20355 001

MAR 07, 1994

DESONIDE

OINTMENT; TOPICAL

DESONIDETARO

0.05%

0.05%

N74254 001

AUG 03, 1994

DEXAMETHASONE

TABLET; ORAL

DECADRONMERCK SHARP DOHME

0.25MG

0.25MG

N11664 004

N11664 004

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXASPORIN

AT BAUSCH AND LOMB0.1%;EQ 3.5MG BASE/GM;
10,000 UNITS/GMN64063 001
JUL 25, 1994DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DECADRON

* MSD

DEXACORT

+ ADAMS LABS

EQ 0.1MG PHOSPHATE/INH

N14242 001
N14242 001

AEROSOL; METERED; INHALATION

DECADRON

* MSD

DEXACORT

+ MEDEVA

EQ 0.1MG PHOSPHATE/INH

N13413 001
N13413 001

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

PHARMAFAIR

EQ 0.1% PHOSPHATE

N88433 001
DEC 15, 1983
N88433 001
DEC 15, 1983

EQ 0.1% PHOSPHATE

DEXTROAMPHETAMINE SULFATE

ELIXIR; ORAL

DEXEDRINE

SMITHKLINE BEECHAM

c

5MG/5ML
5MG/5ML

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

LANNETT

5MG

10MG

15MG

5MG

10MG

15MG

AA
AADEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ DEXTROMETHORPHANAA PENNEX

15MG/5ML; 6.25MG/5ML

N88864 001
JAN 04, 1985
N88864 001
JAN 04, 1985

c PENNEX PHARMS

15MG/5ML; 6.25MG/5ML

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINERAP MCGAW

N16730 002

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

BOOTS

* +

c

4MG

6MG

4MG

6MG

N12302 004
N12302 006
N12302 004
N12302 006DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

CARDIOGRAFIN

c BRACCO DXS

c SQUIBB

RENO-60

BRACCO DXS

RENO-DIP

BRACCO DXS

RENO-M-60

SQUIBB

RENO-M-DIP

SQUIBB

SOLUTION; URETERAL

RENO-30

BRACCO DXS

RENO-M-30

SQUIBB

N11620 002
N11620 002

N10040 016

N10040 012

N10040 016

N10040 012

N10040 021

N10040 021

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
AA DIPHENHYDRAMINE HCL
 @ ROXANE
50MG
50MG

N80835 001
N80635 001

> DLT >
 > DLT >

200MG/100ML

N63165 002
JAN 30, 1991

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AT DIPIVEFRIN HCL
 @ ALCON
0.1%

N73636 001
JUN 30, 1994

AT PROPINE
 @ ALLERGAN
0.1%

N18239 001

AN

99.9%

N74396 001
JUL 29, 1994

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP DOBUTAMINE HCL
 @ BEDFORD

> ADD >
 > ADD >

N74277 001
OCT 31, 1994

EQ 12.5MG BASE/ML

AP DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ ABBOTT

N20201 006
JUL 07, 1994
N20255 005
OCT 19, 1993

EQ 400MG BASE/100ML

EQ 400MG BASE/100ML

50,000 IU
50,000 IU

50,000 IU
50,000 IU

N80884 001
N80884 001

DOXEPIIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON
 @ GENDERM

N20126 001
APR 01, 1994

5%

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

AB ERYC
 @ PARKE DAVIS

N62546 001
JUL 25, 1985

N62546 001
JUL 25, 1985

250MG

250MG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

AP DOXORUBICIN PFS
 @ PHARMACIA

N50629 002
MAY 03, 1988

200MG/100ML

N63165 002
JAN 30, 1991

200MG/100ML

N50629 002
MAY 03, 1988

200MG/100ML

250MG

250MG

OINTMENT; OPHTHALMIC

AT ERYTHROMYCIN
 @ BAUSCH AND LOMB

0.5%

N64067 001
JUL 29, 1994

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

FOUGERA

0.5%

5MG/GM

N62447 001

SEP 26, 1983

N62447 001

SEP 26, 1983

ERYTHROMYCIN

FOUGERA

0.5%

5MG/GM

N50368 001

N50368 001

SOLUTION; TOPICAL

ERYTHROMYCIN

BARRE

2%

N62957 001

JUL 21, 1988

N62957 001

JUL 21, 1988

N64039 001

JAN 27, 1994

N62616 001

JUL 25, 1985

N62616 001

JUL 25, 1985

TABLET, COATED PARTICLES; ORAL

PCE

ABBOTT

333MG

+

333MG

N50611 001

SEP 09, 1986

N50611 001

SEP 09, 1986

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

DISTA

EQ 200MG BASE/5ML

EQ 400MG BASE/5ML

EQ 200MG BASE/5ML

EQ 400MG BASE/5ML

EQ 200MG BASE/5ML

EQ 400MG BASE/5ML

EQ 200MG BASE/5ML

EQ 400MG BASE/5ML

EQ 200MG BASE/5ML

EQ 400MG BASE/5ML

N62177 001

N62177 002

N62177 001

N62177 002

N62559 001

MAR 15, 1985

N62558 001

MAR 15, 1985

N62559 001

MAR 15, 1985

N62558 001

MAR 15, 1985

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL

E.E.S. 400

ABBOTT

EQ 400MG BASE

EQ 400MG BASE

EQ 400MG BASE

EQ 400MG BASE

EQ 400MG BASE

EQ 400MG BASE

N61905 001

N61905 002

AUG 12, 1982

N61905 002

AUG 12, 1982

N61905 001

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYPAR

PARKE DAVIS

@ WARNER CHILCOTT

ERYTHROMYCIN STEARATE

PUREPAC

@ PUREPAC PHARM

EQ 250MG BASE

EQ 250MG BASE

EQ 250MG BASE

EQ 250MG BASE

EQ 250MG BASE

N62322 001

N62322 001

N61743 001

N61743 001

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADERM

+ CIBA

0.05MG/24HR

0.1MG/24HR

N19081 002

SEP 10, 1986

N19081 003

SEP 10, 1986

VIVELLE

NOVEN

0.05MG/24HR

0.1MG/24HR

0.0375MG/24HR

0.075MG/24HR

N20323 002

OCT 28, 1994

N20323 004

OCT 28, 1994

N20323 001

OCT 28, 1994

N20323 003

OCT 28, 1994

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELADUMONE

+ SQUIBB

4MG/ML; 90MG/ML

4MG/ML; 90MG/ML

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

STERIS

4MG/ML; 90MG/ML

N09545 001

N09545 001

N85855 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
 + STERIS 4MG/ML; 90MG/ML

N85865 001

ESTROGENS, ESTERIFIED

TABLET; ORAL

ESTRATAB
 SOLVAY

BS 0.625MG
 BS 0.625MG
 BS 2.5MG
 BS 2.5MG

BS * MENEST
 BS * SMITHKLINE BEECHAM

BS 0.625MG
 BS 0.625MG
 BS 2.5MG
 BS 2.5MG

ESTRONE

INJECTABLE; INJECTION

ESTRONE
 STERIS

BP 2MG/ML
 @ 2MG/ML

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL
 MYAMBUTOL
 LEDERLE

+ 200MG
 @ 400MG
 + 500MG
 @ 200MG
 @ 400MG
 @ 500MG

ETHINAMATE

CAPSULE; ORAL
 VALMID
 DISTA
 @

500MG
 500MG

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28
 NORQUEST FE
 * SYNTHEX

0.035MG; 75MG; 1MG N18926 001
 JUL 18, 1986
 0.035MG; 75MG; 1MG N18926 001
 JUL 18, 1986

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
 NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
 WATSON

AB 0.035MG; 0.035MG; 0.5MG, 1MG N71041 001
 SEP 24, 1991
 ORTHO-NOVUM 7/14-21
 AB + JOHNSON RW 0.035MG; 0.035MG; 0.5MG, 1MG N19004 001
 APR 04, 1984

@ 0.035MG; 0.035MG; 0.5MG, 1MG N19004 001
 APR 04, 1984

TABLET; ORAL-28
 NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
 WATSON

AB 0.035MG; 0.035MG; 0.5MG, 1MG N71042 001
 SEP 24, 1991
 ORTHO-NOVUM 7/14-28
 AB + JOHNSON RW 0.035MG; 0.035MG; 0.5MG, 1MG N19004 002
 APR 04, 1984

@ 0.035MG; 0.035MG; 0.5MG, 1MG N19004 002
 APR 04, 1984

ETODOLAC

TABLET; ORAL
 LODINE
 + WYETH AYERST

400MG N18922 004
 JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE
GENSIA

20MG/ML

N74284 001
FEB 10, 1994

AP
VEPESID
+ BRISTOL

20MG/ML

N18768 001
NOV 10, 1983

FAMCICLOVIR

TABLET; ORAL

FAMVIR
+ SMITHKLINE BEECHAM

500MG

N20363 002
JUN 29, 1994

FAMOTIDINE

INJECTABLE; INJECTION

PEPID IN PLASTIC CONTAINER
+ MERCK

0.4MG/ML

N20249 001
FEB 18, 1994

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL
+ ASTRA MERCK

2.5MG

5MG

10MG

MERCK

5MG

10MG

N19834 004
SEP 22, 1994
N19834 001
JUL 25, 1991
N19834 002
JUL 25, 1991
N19834 001
JUL 25, 1991
N19834 002
JUL 25, 1991

> ADD >
> ADD >
> ADD >
> ADD >

FLUCONAZOLE

TABLET; ORAL

DIFLUCAN
+ PRIZER

50MG

N19949 001
JAN 29, 1990

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN
+ PRIZER

100MG

50MG

100MG

150MG

N19949 002
JAN 29, 1990
N19949 001
JAN 29, 1990
N19949 002
JAN 29, 1990
N20322 001
JUN 30, 1994

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18
+ DOWNSTATE CLINCL

6.8-35.7mCi/ML

N20306 001
AUG 19, 1994

FLUMAZENIL

INJECTABLE; INJECTION

MAZICON
+ ROCHE

0.1MG/ML

N20073 001
DEC 20, 1991

ROMAZICON
+ ROCHE

0.1MG/ML

N20073 001
DEC 20, 1991

FLUCINOLONE ACETONIDE

CREAM; TOPICAL
FLUCINOLONE ACETONIDE

0.025%

N40042 001
OCT 31, 1994
N40035 001
OCT 31, 1994

ointment; topical
FLUCINOLONE ACETONIDE

0.025%

N40041 001
SEP 15, 1994

SOLUTION; TOPICAL
FLUCINOLONE ACETONIDE

0.01%

N88449 001
FEB 08, 1984

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
 @ PHARMAFAIR 0.01%

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
 @ CLAY PARK 0.05%
 @
 @ FOUGERA 0.05%
 @
 @ FOUGERA 0.05%

FLUORESCIN SODIUM

INJECTABLE; INJECTION
 FUNDUSCEIN-25
 + CIBA VISION 25%
 + IOLAB 25%

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP
 CIBA VISION 0.1%
 IOLAB 0.1%

FLUOROURACIL

INJECTABLE; INJECTION
 ADRUCIL
 * ADRIA 50MG/ML
 * ADRIA 50MG/ML
 AP + PHARMACIA 50MG/ML
 @ 50MG/ML

FLURANDRENOLIDE

CREAM; TOPICAL
 CORDRAN SP
 * DISTA 0.025%
 + LILLY 0.05%
 + 0.05%

LOTION; TOPICAL

CORDRAN
 * DISTA 0.05%
 + LILLY 0.05%
 OINTMENT; TOPICAL
 CORDRAN
 * DISTA 0.025%
 + LILLY 0.05%
 + 0.05%

TAPE; TOPICAL

CORDRAN
 * DISTA 0.004MG/SQ CM
 + LILLY 0.004MG/SQ CM

FLURBIPROFEN

TABLET; ORAL

ANSAID
 UPJOHN 50MG
 AB + 100MG
 FLURBIPROFEN
 MYLAN 50MG
 AB 100MG

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL
 FLONASE
 + GLAXO 0.05MG/INH

N12806 003
 N12806 002
 N12806 003
 N12806 002

N13790 001
 N13790 001

N12806 004
 N12806 001
 N12806 004
 N12806 001

N16455 001
 N16455 001

N18766 002
 OCT 31, 1988
 N18766 003
 OCT 31, 1988

N74358 001
 JUN 20, 1994
 N74358 002
 JUN 20, 1994

N20121 001
 OCT 19, 1994

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA LANNETT

AA @

AA PUREPAC

AA @ PUREPAC PHARM

1MG

1MG

1MG

1MG

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP MARSAM

AP ORGANON

AP @

AP SANOFI WINTHROP

AP WARNER CHILCOTT

AP @

> ADD >

> ADD >

10MG/ML

10MG/ML

10MG/ML

10MG/ML

10MG/ML

10MG/ML

10MG/ML

10MG/ML

10MG/ML

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS DUPONT

BS DUPONT MERCK

2mCi/ML

2mCi/ML

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB PUREPAC PHARM

AB WATSON LABS

600MG

600MG

> ADD >

> ADD >

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

AT + SCHERING

AT +

AT GENTAFAIR

AT PHARMAFAIR

@

GENTAMICIN

AT CLAY PARK

AT

GENTAMICIN SULFATE

AT BAUSCH AND LOMB

AT

AT FOUGERA

AT

AT

AT

AT

AT

AT

AT

AT

AT

INJECTABLE; INJECTION

APOGEN

AP KING PHARMS

AP

AP SMITHKLINE BEECHAM

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

AP

N60462 001
N60462 001

N62458 001
SEP 01, 1983

N62458 001
SEP 01, 1983

N62307 001
N62307 001

N64056 001
APR 29, 1994

N62531 001
JUL 05, 1984

N62531 001
JUL 05, 1984

N62471 001
SEP 27, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

N62427 001
MAY 26, 1983

GENTAMICIN SULFATE

ointment; ophthalmic

GENTACIDIN
IOLAB

EQ 3MG BASE/GM

N62501 001
JUL 26, 1984

ointment; topical

GARAMYCIN
+ SCHERING

EQ 0.1% BASE
EQ 1MG BASE/GM

N60463 001
N60463 001

GENTAFAIR
PHARMAFAIR

EQ 0.1% BASE
EQ 0.1% BASE

N62444 001
MAY 26, 1983
N62444 001
MAY 26, 1983

GENTAMICIN
CLAY PARK

EQ 0.1% BASE
EQ 1MG BASE/GM

N62351 001
FEB 18, 1982
N62351 001
FEB 18, 1982

GENTAMICIN SULFATE
BAUSCH AND LOMB

EQ 0.1% BASE
EQ 0.1% BASE

N64054 001
APR 29, 1994
N62533 001
OCT 05, 1984

FOUGERA

EQ 1MG BASE/GM

N62533 001
OCT 05, 1984
N62496 001
MAR 14, 1984

NMC

EQ 0.1% BASE

EQ 1MG BASE/GM

N62496 001
MAR 14, 1984
N62534 001
OCT 10, 1984

PHARMADERM

EQ 0.1% BASE

EQ 1MG BASE/GM

N62534 001
OCT 10, 1984
N62477 001
DEC 23, 1983
N62477 001
DEC 23, 1983

THAMES

EQ 0.1% BASE

EQ 1MG BASE/GM

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN
+ SCHERING

EQ 0.3% BASE
EQ 3MG BASE/ML

N50039 002
N50039 002
N62452 001
OCT 10, 1984

GENOPTIC
ALLERGAN

EQ 0.3% BASE

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC
ALLERGAN

EQ 3MG BASE/ML

N62452 001
OCT 10, 1984

GENTACIDIN
IOLAB

EQ 0.3% BASE

N62480 001
MAR 30, 1984
N62480 001
MAR 30, 1984

GENTAFAIR
@ PHARMAFAIR

EQ 0.3% BASE

N62440 001
MAY 03, 1983

GENTAMICIN SULFATE
AKORN

EQ 0.3% BASE

N62635 001
JAN 08, 1987
N62635 001
JAN 08, 1987

BAUSCH AND LOMB

EQ 0.3% BASE

N64048 001
MAY 11, 1994
N62523 001
NOV 25, 1985
N62523 001
NOV 25, 1985

STERIS

EQ 0.3% BASE

EQ 3MG BASE/ML

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

MYLAN

5MG

N74226 001
MAY 10, 1994
N74226 002
MAY 10, 1994

10MG

GLUCOTROL
Pfizer

5MG

N17783 001
MAY 08, 1984
N17783 002
MAY 08, 1984

10MG

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL

+ Pfizer

5MG

N20329 001
APR 26, 1994
N20329 002
APR 26, 1994

10MG

GLUTETHIMIDE

TABLET; ORAL

GLUTETHIMIDE

HALSEY

250MGN89458 001
OCT 10, 1986

250MG

N89458 001

LANNETT

250MGN83475 001
OCT 10, 1986500MG

N85571 001

250MG

N83475 001

500MG

N85571 001

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

FUJISAWA

0.2MG/MLN88475 001
JUN 12, 1984

0.2MG/ML

N88475 001
JUN 12, 1984GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

WYETH AYERST

AP +

N17055 003

N17055 003

CHORIONIC GONADOTROPIN

FUJISAWA

5,000 UNITS/VIAL

N17067 001

20,000 UNITS/VIAL

N17067 003

5,000 UNITS/VIAL

N17067 001

20,000 UNITS/VIAL

N17067 003

20,000 UNITS/VIAL

N17016 004

15,000 UNITS/VIAL

N17016 010

15,000 UNITS/VIAL

FEB 15, 1985

15,000 UNITS/VIAL

N17016 010

20,000 UNITS/VIAL

FEB 15, 1985

20,000 UNITS/VIAL

N17016 004

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR

0.025MG/ML; EQ 1.75MG BASE/ML

N62383 001

10,000 UNITS/ML

AUG 31, 1982

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR

0.025MG/ML; EQ 1.75MG BASE/ML

N62383 001

10,000 UNITS/ML

AUG 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

KYTRIL

* SMITHKLINE BEECHAM

EQ 3MG BASE/ML

N20239 001

EQ 1MG BASE/ML

N20239 002

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

EQ 3MG BASE/ML

N20239 001

HEPARIN SODIUMINJECTABLE; INJECTIONHEPARIN SODIUMAKORN

> DLT >	AP	1,000 UNITS/ML	N17486 001
> DLT >	AP	5,000 UNITS/ML	N17486 002
> DLT >	AP	10,000 UNITS/ML	N17486 003
> DLT >	AP	20,000 UNITS/ML	N17486 004
> DLT >	AP	40,000 UNITS/ML	N17486 005
> ADD >	@	1,000 UNITS/ML	N17486 001
> ADD >	@	5,000 UNITS/ML	N17486 002
> ADD >	@	10,000 UNITS/ML	N17486 003
> ADD >	@	20,000 UNITS/ML	N17486 004
> ADD >	@	40,000 UNITS/ML	N17486 005

HEXACHLOROPHENEEMULSION; TOPICALPHISOHEX

> ADD >	+	SANOFI WINTHROP	3%	N06882 001
> DLT >	+	STERLING WINTHROP	3%	N06882 001

SPONGE; TOPICALPHISO-SCRUB

> ADD >	@	SANOFI WINTHROP	3%	N17446 001
> DLT >	@	STERLING WINTHROP	3%	N17446 001

HYDRALAZINE HYDROCHLORIDETABLET; ORALHYDRALAZINE HCL
AMIDE PHARM

AA	25MG	N88560 001
AA	50MG	OCT 04, 1984
		N88649 001
		OCT 18, 1984
@	25MG	N88560 001
@	50MG	OCT 04, 1984
		N88649 001
		OCT 18, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINETABLET; ORAL

BP	RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	N87556 001
		25MG;15MG;0.1MG
@	DANBURY PHARMA	25MG;15MG;0.1MG

HYDROCHLOROTHIAZIDETABLET; ORALHYDROCHLOROTHIAZIDE

AB	WEST WARD	25MG	N84899 001
@	WEST WARD PHARM	25MG	N84899 001
AB	ZENITH	50MG	N84658 001
@	ZENITH LABS	50MG	N84658 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDETABLET; ORALNORMOZIDE

+	SCHERING	25MG;100MG	N19046 001
			APR 06, 1987
@		25MG;200MG	N19046 002
			APR 06, 1987
@		25MG;300MG	N19046 003
			APR 06, 1987
@		25MG;100MG	N19046 001
			APR 06, 1987
@		25MG;200MG	N19046 002
			APR 06, 1987
@		25MG;300MG	N19046 003
			APR 06, 1987

HYDROCHLOROTHIAZIDE; RESERPINETABLET; ORALHYDROCHLOROTHIAZIDE W/ RESERPINE

BP	ROXANE	50MG;0.125MG	N84603 001
@		50MG;0.125MG	N84603 001

HYDROCHLOROTHIAZIDE; TRIAMTERENECAPSULE; ORALDYAZIDE

AB	SMITHKLINE BEECHAM	25MG;50MG	N16042 002
		25MG;37.5MG	N16042 003
@		25MG;50MG	MAR 03, 1994
			N16042 002

TRIAMTERENE AND HYDROCHLOROTHIAZIDEGENEVA PHARMS

AB		25MG;50MG	N73191 001
+		25MG;50MG	JUL 31, 1991
			N73191 001
			JUL 31, 1991

HYDROCORTISONECREAM; TOPICAL
HYDROCORTISONE

AT	1%	N85191 001	1%	AT	1%	N85191 001
AT	1%	N87838 001	1%	AT	1%	N87838 001
		JUL 28, 1982				JUL 28, 1982
		N87838 001				N87838 001
		JUL 28, 1982				JUL 28, 1982

ENEMA; RECTAL
CORTENEMA
+ SOLVAY

AT	100MG/60ML	N16199 001
AT	100MG/60ML	N74171 001
		MAY 27, 1994

GEL; TOPICAL
HYDROCORTISONE

AT	1%	N84698 001
AT	1%	N88215 001
		JUN 06, 1984
		N88215 001
		JUN 06, 1984

PENECORT
ALLERGAN HERBERTLOTION; TOPICAL
HYDROCORTISONE

AT	1%	N85663 001
AT	1%	N85663 001

OINTMENT; TOPICAL
HYDROCORTISONE

AT	1%	N85028 001
AT	1%	N85028 001

TABLET; ORAL

HYDROCORTISONE

BP	20MG	N80355 001
BP	20MG	N80355 001
BP	20MG	N80732 001
BP	20MG	N80732 001

INWOOD LABS

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

AT	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62394 001
		SEP 29, 1982
		N62394 001
		SEP 29, 1982
		N62394 001
		SEP 29, 1982

SUSPENSION; OTIC

OTICAIR

AT	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62399 001
		NOV 18, 1982
		N62399 001
		NOV 18, 1982
		N62399 001
		NOV 18, 1982

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

AT	1%	N89914 001
		JAN 03, 1989
		N89914 001
		JAN 03, 1989
		N89914 001
		JAN 03, 1989

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

BP	50MG/ML	N85214 001
BP	50MG/ML	N85214 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

AT	1%; 10%	N80505 001
AT	1%; 10%	N80505 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOLD	0.1%	N18514 001
BROCADES PHARMA	0.1%	MAR 31, 1982

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
+ YAMANOUCHI

0.1%

N18514 001
MAR 31, 1982

OINTMENT; TOPICAL

LOCOID
@ BROCADES PHARMA

0.1%

N18652 001
OCT 29, 1982
N18652 001
OCT 29, 1982

@ YAMANOUCHI

0.1%

SOLUTION; TOPICAL

LOCOID
* BROCADES PHARMA

0.1%

N19116 001
FEB 25, 1987
N19116 001
FEB 25, 1987

+ YAMANOUCHI

0.1%

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT
ABBOTT

AP

EQ 250MG BASE/VIAL

N89578 001
APR 11, 1989

AP

EQ 500MG BASE/VIAL

N89579 001
APR 11, 1989

AP

EQ 1GM BASE/VIAL

N89580 001
APR 11, 1989

@

EQ 250MG BASE/VIAL

N89578 001
APR 11, 1989

@

EQ 500MG BASE/VIAL

N89579 001
APR 11, 1989

@

EQ 1GM BASE/VIAL

N89580 001
APR 11, 1989

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID-HP
+ KNOLL PHARM

250MG/VIAL

N19034 002
AUG 04, 1994

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

AB
HYDROXYCHLOROQUINE SULFATE
COPLEY PHARM

200MG

N40081 001
SEP 30, 1994

PLAQUENIL

> ADD > AB + SANOFI WINTHROP 200MG
> DLT > AB + STERLING WINTHROP 200MG

N09768 001
N09768 001

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN
* SQUIBB

125MG/ML

N10347 004

125MG/ML

N16911 001

250MG/ML

N10347 002

250MG/ML

N16911 002

125MG/ML

N10347 004

125MG/ML

N16911 001

250MG/ML

N10347 002

250MG/ML

N16911 002

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N18004 001

125MG/ML

N18004 001

125MG/ML

N17439 001

250MG/ML

N17439 002

125MG/ML

N17439 001

250MG/ML

N17439 002

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL
SMITH KEEFE SOLOPAK

25MG/ML

N87591 001

50MG/ML

N87593 001

50MG/ML

N87595 001

25MG/ML

N87591 001

50MG/ML

N87593 001

50MG/ML

N87595 001

ORGATRAK

25MG/ML

N87014 001

50MG/ML

N87014 002

25MG/ML

N87014 001

50MG/ML

N87014 002

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 10 / JAN'94 - OCT'94

27

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HCL
HI TECH PHARMA

10MG/5ML

N40010 001
OCT 28, 1994

AB
INDOMETHACIN

25MG

N18690 001
JUL 31, 1984
N18690 002
JUL 31, 1984

TABLET; ORAL

HYDROXYZINE HCL
AMIDE PHARM

10MG

N89071 001
JUL 22, 1986
N89072 001
JUL 22, 1986
N89073 001
JUL 22, 1986

@ CHELSEA LABS

50MG
25MG
50MG

N18690 001
JUL 31, 1984
N18690 002
JUL 31, 1984

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R
+ LILLY

500 UNITS/ML

N18780 004
MAR 31, 1994

INVERT SUGAR

INJECTABLE; INJECTION
TRAVERS 10% IN PLASTIC CONTAINER
BAXTER
@
10GM/100ML
10GM/100ML

N16717 001
N16717 001

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME
+ GENZYME

200 UNITS/VIAL

N20367 001
MAY 23, 1994

IOBENGUANE SULFATE I 131
INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131
CIS
2.3mCi/ML

N20084 001
MAR 25, 1994

INDIUM IN-111 PENTETROTIDE KIT

INJECTABLE; INJECTION
OCTEOSCAN
MALLINCKRODT

3mCi/ML

N20314 001
JUN 02, 1994

INJECTABLE; INJECTION
RENOVUE-65
+ BRACCO DXS
* SQUIBB

65%
65%

N17902 001
N17902 001

IODIPAMIDE MEGGLUMINE

INJECTABLE; INJECTION
CHOLOGRAFIN MEGGLUMINE
+ BRACCO DXS
+ SQUIBB
+ SQUIBB

10.3%
52%
10.3%
52%

IODIPAMIDE SODIUM

INJECTABLE; INJECTION
CHOLOGRAFIN SODIUM
+ BRACCO DXS
+ SQUIBB

20%
20%

IODOHIPPURATE SODIUM, I-123

INJECTABLE; INJECTION
NEPHROFLOW
MEDI PHYSICS

1mCi/ML
1mCi/ML

IODOXAMATE MEGGLUMINE

INJECTABLE; INJECTION
CHOLOVUE
+ BRACCO DXS
+ SQUIBB
+ SQUIBB

9.9%
40.3%
9.9%
40.3%

IOHEXOL

SOLUTION; URETHRAL
OMNIPAQUE 70
+ STERLING WINTHROP

15.1%

IOPAMIDOL

INJECTABLE; INTRAVASCULAR

ISOVUE-200
BRACCO DXS

41%

ISOVUE-250
BRACCO DXS

51%

ISOVUE-300
BRACCO DXS

61%

ISOVUE-370
BRACCO DXS

76%

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM
BRACCO DXS
SQUIBB

N12968 001
N12968 001

IPODATE SODIUM

CAPSULE; ORAL
ORAGRAFIN SODIUM
BRACCO DXS
SQUIBB

N12967 001
N12967 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
BRONKOSOL
+ SANOFI WINTHROP
+ SQUIBB
+ SQUIBB

N12339 008
N12339 009
N12339 008
N12339 009

1%
0.25%
1%
0.25%

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER
+ SANOFI WINTHROP
+ SQUIBB

N12339 007
N12339 007

0.34MG/INH
0.34MG/INH

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE
AN INHALON

99.9%

N74416 001
SEP 30, 1994

TABLET; ORAL

BX * ISMO
+ WYETH

20MG

N19091 001
DEC 30, 1991

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER
+ MARION MERRELL DOW 50MG; 300MG; 120MG

N50705 001
MAY 31, 1994

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISUPREL
+ SANOFI WINTHROP 0.131MG/INH
* STERLING WINTHROP 0.131MG/INH

> ADD >
> DLT >

INJECTABLE; INJECTION

ISUPREL
+ SANOFI WINTHROP 0.2MG/ML
* STERLING WINTHROP 0.2MG/ML

> ADD >
> DLT >

SOLUTION; INHALATION

ISUPREL 0.5%
+ SANOFI WINTHROP 1%
* STERLING WINTHROP 0.5%
* 1%

> ADD >
> ADD >
> DLT >
> DLT >

TABLET; RECTAL, SUBLINGUAL

ISUPREL
@ SANOFI WINTHROP 10MG
@ 15MG
@ STERLING WINTHROP 10MG
@ 15MG

> ADD >
> ADD >
> ADD >
> DLT >
> DLT >

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

AB + WYETH

20MG

N19091 001
DEC 30, 1991

ISOSORBIDE MONONITRATE

TABLET; ORAL

BX * ISMO
+ WYETH

20MG

N19091 001
DEC 30, 1991

AB MONOKET

SWARZ PHARMA

20MG

N20215 001
JUN 30, 1993

BX SWARZ PHARMA

20MG

N20215 001
JUN 30, 1993

ISRADIPINE

CAPSULE; ORAL

DYNACIRC
SANDOZ

5MG

N19546 002
DEC 20, 1990

+

5MG

N19546 002
DEC 20, 1990

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR
+ SANDOZ

5MG

N20336 001
JUN 01, 1994

+

10MG

N20336 002
JUN 01, 1994

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX
+ APOTHECON

EQ 500MG BASE
EQ 500MG BASE

N61911 001
MAR 06, 1987

@

EQ 500MG BASE

N60516 001

@

EQ 500MG BASE

N61911 001

+

EQ 500MG BASE

N62726 001

+

EQ 500MG BASE

MAR 06, 1987

AB * BRISTOL

EQ 500MG BASE

N60516 001

INJECTABLE; INJECTION

KANTREX

* APOTHECON

EQ 75MG BASE/2ML

N61655 003

AP

EQ 75MG BASE/2ML

N61901 003

AP

EQ 75MG BASE/2ML

N61901 003

AP

EQ 500MG BASE/2ML

N61655 001

KANAMYCIN SULFATE

INJECTABLE; INJECTION

AP KANTREX
 AP APOTHECON

AP +
 AP *
 AP *
 AP +
 AP @
 AP @

EQ 500MG BASE/2ML
 EQ 500MG BASE/2ML
 EQ 1GM BASE/3ML
 EQ 1GM BASE/3ML
 EQ 1GM BASE/3ML
 EQ 75MG BASE/2ML
 EQ 75MG BASE/2ML
 EQ 500MG BASE/2ML
 EQ 500MG BASE/2ML
 EQ 1GM BASE/3ML
 EQ 1GM BASE/3ML
 EQ 75MG BASE/2ML
 EQ 500MG BASE/2ML
 EQ 1GM BASE/3ML

AP BRISTOL

AP
 AP
 AP

KLEBCIL

@ KING PHARMS

@
 @
 @
 @
 @
 @
 @

SMITHKLINE BEECHAM

EQ 75MG BASE/2ML
 EQ 500MG BASE/2ML
 EQ 1GM BASE/3ML

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

AP LEUCOVORIN CALCIUM

@ ELKINS SINN

* IMMUNEX

@

EQ 100MG BASE/VIAL

EQ 3MG BASE/ML
 EQ 3MG BASE/ML

LEVONUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AT BETAGAN

+ ALLERGAN

0.25%

LEVONUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AT BETAGAN

+ ALLERGAN

0.5%

AT LEVONUNOLOL HCL

+ BAUSCH AND LOMB

0.25%

AT

0.5%

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

+ CIBA VISION

EQ 0.05% BASE

* IOLAB

EQ 0.05% BASE

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP ARESTOCALINE HCL W/ LEVONORDEFRIN

@ CARLISLE

0.05MG/ML; 2%

@ SOLVAY

0.05MG/ML; 2%

AP CARBOCAINE W/ NEO-COBEFRIN

* COOK WAITE

0.05MG/ML; 2%

AP EASTMAN KODAK

0.05MG/ML; 2%

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP RAVOCALINE AND NOVOCALIN W/ NEO-COBEFRIN

@ EASTMAN KODAK

0.05MG/ML; 2%; 0.4%

@ STERLING WINTHROP

0.05MG/ML; 2%; 0.4%

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

AT MYLOCAINE

PENNEX

4%

N19814 001

JUN 28, 1989

AT

4%

N87881 001
 NOV 18, 1982

N19219 002
 DEC 19, 1985
 N74307 001
 MAR 04, 1994
 N74326 001
 MAR 04, 1994

N20219 001
 NOV 10, 1993
 N20219 001
 NOV 10, 1993

N85010 001
 N85010 001
 N12125 002
 N12125 002

N08592 007
 N08592 007

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

MYLOCAINE
@ PENNEX PHARMS

PEDIATRIC LTA KIT
ABBOTT

AT

4%

2%

2%

N87881 001
NOV 18, 1982

N88572 001
JUL 31, 1984
N88572 001
JUL 31, 1984

> DLT >
> ADD >

AA
AA

SYRUP; ORAL
CIBALITH-S
CIBA
SOLVAY

EQ 300MG CARBONATE/5ML
EQ 300MG CARBONATE/5ML

N17672 001
N17672 001

LIOTRIX (T4,T3)

TABLET; ORAL

EUTHROID-0.5
PARKE DAVIS

@

EUTHROID-1
PARKE DAVIS

@

EUTHROID-2
PARKE DAVIS

@

EUTHROID-3
PARKE DAVIS

* @

0.03MG;0.0075MG
0.03MG;0.0075MG

0.06MG;0.015MG
0.06MG;0.015MG

0.12MG;0.03MG
0.12MG;0.03MG

0.18MG;0.045MG
0.18MG;0.045MG

N16680 001
N16680 001

N16680 002
N16680 002

N16680 003
N16680 003

N16680 004
N16680 004

N18140 001
N18140 002
N74280 001
MAY 27, 1994
N74282 001
MAY 27, 1994
N74280 002
MAY 27, 1994
N74282 002
MAY 27, 1994
N74276 001
APR 15, 1994
N74276 002
APR 15, 1994
N74243 001
APR 12, 1994
N74300 001
APR 12, 1994
N74243 002
APR 12, 1994

2MG/ML
4MG/ML
2MG/ML
2MG/ML
4MG/ML
4MG/ML
2MG/ML
4MG/ML
2MG/ML
2MG/ML
2MG/ML
4MG/ML

INJECTABLE; INJECTION
ATIVAN
+ WYETH AYERST
+
LORAZEPAM
ABBOTT

AP
AP
AP
AP
AP
AP
AP
AP
AP
AP
AP
AP

TABLET; ORAL

PRINIVIL
MERCK

@

ZESTRIL
ZENECA

@

2.5MG

2.5MG

N19558 006
JAN 28, 1994

N19777 005
APR 29, 1993

AB

AB

TABLET; ORAL
LORAZEPAM
WARNER CHILCOTT

1MG

2MG

1MG

2MG

N71038 001
JAN 12, 1988
N71039 001
JAN 12, 1988
N71038 001
JAN 12, 1988
N71039 001
JAN 12, 1988

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHOBID

@ CIBA

@ SOLVAY

300MG
300MG

N18027 001
N18027 001

> DLT >
> ADD >

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER
ABBOTT

4GM/100ML
80MG/ML
N20309 001
JUN 24, 1994
N20309 002
JUN 24, 1994

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL
@ SOLVAY

3%
N84777 002
APR 18, 1982

> DLT >
> ADD >
CARBOCAINE
* COOK WHITE
AP + EASTMAN KODAK

3%
N12125 003
N12125 003

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA
UPJOHN

150MG/ML
150MG/ML
N20246 001
OCT 29, 1992
N20246 001
OCT 29, 1992

TABLET; ORAL

MEPRIAM
LEMMON
@

400MG
400MG
N16069 001
N16069 001

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION
HUMEGON
ORGANON

> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >
75 IU/VIAL; 75 IU/VIAL
150 IU/VIAL; 150 IU/VIAL
75 IU/VIAL; 75 IU/VIAL
150 IU/VIAL; 150 IU/VIAL

N20328 001
SEP 01, 1994
N20328 002
SEP 01, 1994
N20328 001
SEP 01, 1994
N20328 002
SEP 01, 1994

PERGONAL
+ SERONO
+ *

75 IU/AMP; 75 IU/AMP
150 IU/AMP; 150 IU/AMP
75 IU/AMP; 75 IU/AMP
150 IU/AMP; 150 IU/AMP

N17646 001
N17646 002
MAY 20, 1985
N17646 001
N17646 002
MAY 20, 1985

* SERONO LABS
*

25MG
50MG
N40062 001
JAN 27, 1994
N40062 002
JAN 27, 1994

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL
CARLISLE

3%
N84777 002
APR 18, 1982

METHDILAZINE

TABLET CHEWABLE; ORAL
TACARYL
WESTWOOD SQUIBB
@

3.6MG
3.6MG
N11950 009
N11950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL
TACARYL
WESTWOOD SQUIBB

4MG/5ML
N11950 007

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL
TACARYL
@ WESTWOOD SQUIBB

4MG/5ML

N11950 007

TABLET; ORAL

TACARYL
WESTWOOD SQUIBB
@

8MG
8MG

N11950 006
N11950 006

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX PFS
ADRIA

AP

EQ 25MG BASE/ML

N89180 001

@ PHARMACIA

EQ 25MG BASE/ML

N89180 001
JAN 03, 1986
JAN 03, 1986

TABLET; ORAL

METHOTREXATE SODIUM
ROXANE

AB

EQ 2.5MG BASE

N40054 001
AUG 01, 1994

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

PAMINE
BRADLEY
KENWOOD LABS

2.5MG
2.5MG

N08848 001
N08848 001

> DLT >
> ADD >

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED
ABBOTT

AP

EQ 40MG BASE/VIAL

N89573 001
FEB 22, 1991

AP

EQ 125MG BASE/VIAL

N89574 001
FEB 22, 1991

AP

EQ 500MG BASE/VIAL

N89575 001
FEB 22, 1991

@

EQ 40MG BASE/VIAL

N89573 001
FEB 22, 1991

@

EQ 125MG BASE/VIAL

N89574 001
FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED
@ ABBOTT

EQ 500MG BASE/VIAL

N89575 001
FEB 22, 1991

METHYLPREDNISOLONE
ORGANON

AP

EQ 500MG BASE/VIAL

N87535 001
JUN 25, 1982

AP

EQ 1GM BASE/VIAL

N87535 002
JUN 25, 1982

EQ 500MG BASE/VIAL

N87535 001
JUN 25, 1982

EQ 1GM BASE/VIAL

N87535 002
JUN 25, 1982

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL

METHYLTESTOSTERONE

@ PRIVATE FORM

5MG

@ PVT FORM

5MG

@ TABLICAPS

10MG

@

10MG

TABLET; ORAL

ANDROID 25

ICON

25MG

AB

25MG

N87147 001

+ METHYLTESTOSTERONE

DANBURY PHARMA

BP

10MG

BP

25MG

N80933 001

BP

10MG

N80933 001

BP

25MG

N80933 001

BP

10MG

N80931 001

BP

25MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

BP

10MG

N80475 002

BP

25MG

N80475 003

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL
@ SCHERING

25MG

N03158 002

50MG100MG

N73288 001

MAR 25, 1994

N73289 001

MAR 25, 1994

N74143 001

SEP 30, 1994

N74143 002

SEP 30, 1994

N74380 001

JUL 29, 1994

N74380 002

JUL 29, 1994

N74217 001

MAY 27, 1994

N74217 002

MAY 27, 1994

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
MAXOLON
KING PHARMS

EQ 10MG BASE

N70106 001

MAR 04, 1986

N70106 001

MAR 04, 1986

EQ 10MG BASE

SMITHKLINE BEECHAM

ABMETOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
TOPROL XL

* HASSLE AB

EQ 50MG TARTRATE

N19962 001

JAN 10, 1992

N19962 002

JAN 10, 1992

N19962 003

JAN 10, 1992

EQ 200MG TARTRATE

TOPROL-XL

+ ASTRA

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

+ +

TABLET; ORAL

METOPROLOL TARTRATE

APOTHECON

50MG

N74258 001

JAN 27, 1994

N74258 002

JAN 27, 1994

N74333 001

JAN 27, 1994

N74333 002

JAN 27, 1994

100MG

COPLEY PHARM

50MG100MGMETOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

GENEVA PHARMS

AB

N03158 002

50MG100MG

N73288 001

MAR 25, 1994

N73289 001

MAR 25, 1994

N74143 001

SEP 30, 1994

N74143 002

SEP 30, 1994

N74380 001

JUL 29, 1994

N74380 002

JUL 29, 1994

N74217 001

MAY 27, 1994

N74217 002

MAY 27, 1994

PUREPAC PHARM

AB

N70106 001

EQ 10MG BASEAB

WATSON LABS

AB

N70106 001

EQ 10MG BASEABMILRINONE LACTATE

INJECTABLE; INJECTION

PRIMACOR

+ SANOFI WINTHROP

* STERLING WINTHROP

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

@ SANOFI WINTHROP

@

+

@ STERLING WINTHROP

@

+

@ STERLING WINTHROP

@

+

@ STERLING WINTHROP

@

+

@ STERLING WINTHROP

@

+

> ADD >

> ADD >

> DLT >

> DLT >

> DLT >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

> ADD >

N19436 001

DEC 31, 1987

N19436 001

DEC 31, 1987

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

N20343 001

AUG 09, 1994

N20343 002

AUG 09, 1994

N20343 003

AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL

MINOCIN

© LEDERLE

®

EQ 50MG BASE

EQ 100MG BASE

MINOCYCLINE HCL

LEDERLE

EQ 50MG BASE

EQ 100MG BASE

N50451 003

AUG 10, 1982

N50451 002

AUG 10, 1982

N50451 003

AUG 10, 1982

N50451 002

AUG 10, 1982

AP

AP

AP

AP

AP

AP

AP

AP

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 4GM BASE/VIAL

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

EQ 4GM BASE/VIAL

UNIPEN

WYETH AVERST

®

N61984 001

N61984 002

N61984 003

N61984 005

N61984 001

N61984 002

N61984 003

N61984 005

EQ 10GM BASE/VIAL

EQ 20GM BASE/VIAL

N50320 005

N50320 006

MITOMYCIN

INJECTABLE; INJECTION

MITAMYCIN

© BRISTOL

®

> DLT >

> DLT >

> ADD >

> DLT >

> DLT >

> ADD >

> DLT >

> DLT >

> ADD >

> DLT >

> DLT >

> ADD >

5MG/VIAL

20MG/VIAL

5MG/VIAL

20MG/VIAL

5MG/VIAL

20MG/VIAL

5MG/VIAL

20MG/VIAL

40MG/VIAL

N50450 001

N50450 002

N50450 001

N50450 002

N50450 001

N50450 002

N50450 001

N50450 002

N50450 001

N50450 002

N50450 001

N50450 002

> ADD >

> DLT >

SUSPENSION; ORAL

NEGRAM

+ SANOFI WINTHROP

+ STERLING WINTHROP

250MG/5ML

250MG/5ML

N17430 001

N17430 001

TABLET; ORAL

NEGRAM

SANOFI WINTHROP

+ STERLING WINTHROP

250MG

500MG

1GM

250MG

500MG

1GM

N14214 002

N14214 004

N14214 005

N14214 002

N14214 004

N14214 005

NADOLOL

TABLET; ORAL

CORGARD

SQUIBB

+

120MG

120MG

160MG

160MG

N18063 003

N18063 003

N18063 004

N18063 004

> ADD >

> ADD >

> DLT >

> DLT >

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

+ ORGANON

DURABOLIN-50

+ ORGANON

50MG/ML

50MG/ML

N11891 002

N11891 002

NADOLOL

COPLY PHARM

80MG

120MG

N74368 001

AUG 31, 1994

N74368 002

AUG 31, 1994

N74368 003

AUG 31, 1994

SOLUTION/DROPS; OPHTHALMIC

NAPAZOLIN

BAUSCH AND LOMB

0.1%

N40073 001

MAY 25, 1994

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AT NAFAZOLIN 0.1%

@ PHARMACEUTICAL

AT VASOCIN

0.1%

AT CIBA VISION

0.1%

AT IOLEAB

> ADD >
> ADD >
> DLT >
> DLT >

N88101 001

APR 15, 1983

N88101 001

APR 15, 1983

N80235 002

MAR 24, 1983

N80235 002

MAR 24, 1983

NAPROXEN

SUSPENSION; ORAL

AB NAPROSIN 25MG/ML

+ SYNTEX

AB NAPROXEN 25MG/ML

+ ROXANE

AB NAPROXEN 25MG/ML

+ ROXANE

TABLET; ORAL

AB NAPROSIN 500MG

+ SYNTEX

AB NAPROXEN 500MG

+ ROXANE

AB NAPROXEN 250MG

+ ROXANE

AB NAPROXEN 375MG

+ ROXANE

AB NAPROXEN 500MG

+ ROXANE

TABLET, DELAYED RELEASE; ORAL

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

EC-NAPROSIN

+ SYNTEX

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

N20067 002

OCT 14, 1994

N20067 003

OCT 14, 1994

NAPROXEN SODIUM

TABLET; ORAL

AB NAPROXEN SODIUM EQ 250MG BASE

+ COPLEY PHARM

AB NAPROXEN SODIUM EQ 500MG BASE

+ COPLEY PHARM

AB NAPROXEN SODIUM EQ 250MG BASE

+ MYLAN

AB NAPROXEN SODIUM EQ 500MG BASE

+ MYLAN

N74289 001

JAN 27, 1994

N74289 002

JAN 27, 1994

N74367 001

AUG 31, 1994

N74367 002

AUG 31, 1994

NEOMYCIN SULFATE

TABLET; ORAL

AA NEOMYCIN SULFATE EQ 350MG BASE

+ LANNETT

@ LANNETT

AA NEOMYCIN SULFATE EQ 350MG BASE

+ LANNETT

@ LANNETT

AA NEOMYCIN SULFATE EQ 350MG BASE

+ LANNETT

@ LANNETT

AA NEOMYCIN SULFATE EQ 350MG BASE

+ LANNETT

@ LANNETT

AA NEOMYCIN SULFATE EQ 350MG BASE

+ LANNETT

@ LANNETT

AA NEOMYCIN SULFATE EQ 350MG BASE

+ LANNETT

@ LANNETT

N60607 001

N60607 001

FILM, EXTENDED RELEASE; TRANSDERMAL

BC HABITROL 7MG/24HR

+ BASEL PHARMS

BC HABITROL 7MG/24HR

+ BASEL PHARMS

BC HABITROL 14MG/24HR

+ BASEL PHARMS

BC HABITROL 14MG/24HR

+ BASEL PHARMS

BC HABITROL 21MG/24HR

+ BASEL PHARMS

BC HABITROL 21MG/24HR

+ BASEL PHARMS

N20076 001

NOV 27, 1991

N20076 001

NOV 27, 1991

N20076 002

NOV 27, 1991

N20076 002

NOV 27, 1991

N20076 003

NOV 27, 1991

N20076 003

NOV 27, 1991

NITROFURANTOIN

TABLET; ORAL

AB NITROFURANTOIN 50MG

+ LANNETT

@ LANNETT

AB NITROFURANTOIN 100MG

+ LANNETT

@ LANNETT

AB NITROFURANTOIN 100MG

+ LANNETT

@ LANNETT

N80017 001

N80017 001

N80017 002

N80017 002

N80017 001

N80017 001

N80017 002

N80017 002

NITROFURAZONE

OINTMENT; TOPICAL

NITROFURAZONE

LANNETT

0.2%
0.2%N84393 001
N84393 001> ADD >
> ADD >
> DLT >
> DLT >N08592 003
N08592 003NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

INTL MEDICATION

5MG/ML

N70026 001

SEP 10, 1985

5MG/ML

N70026 001

SEP 10, 1985

NITROGLYCERIN IN DEXTROSE 5%

ABBOTT

0.1MG/ML

N74083 001

OCT 26, 1994

> ADD >

> ADD >

NITRONAL

* BOSKAMP

1MG/ML

N18672 001

AUG 30, 1983

1MG/ML

N18672 001

AUG 30, 1983

NITROSTAT

PARKE DAVIS

5MG/ML

N70863 001

JAN 08, 1987

10MG/ML

N70871 001

JAN 08, 1987

10MG/ML

N70872 001

JAN 08, 1987

5MG/ML

N70863 001

JAN 08, 1987

10MG/ML

N70871 001

JAN 08, 1987

10MG/ML

N70872 001

JAN 08, 1987

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

+ SANOFI WINTHROP

* STERLING WINTHROP

EQ 1MG BASE/ML
EQ 1MG BASE/MLN07513 001
N07513 001> ADD >
> ADD >
> DLT >
> DLT >N63010 001
DEC 20, 1988
N63010 001
DEC 20, 1988NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK

EQ 0.033MG BASE/ML; 2%;

0.4%

EQ 0.033MG BASE/ML; 2%;

0.4%

N08592 003
N08592 003NORETHINDRONE

TABLET; ORAL

NORLUTIN

* PARKE DAVIS

@

5MG

5MG

N10895 002
N10895 002NYSTATIN

SUSPENSION; ORAL

NYSTATIN

BAUSCH AND LOMB

100,000 UNITS/ML

N64042 001

FEB 28, 1994

N62541 001

JAN 16, 1985

N62541 001

JAN 16, 1985

JAN 16, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCOLOG-II

+ APOTHECON

100,000 UNITS/GM; 0.1%

N60576 002

MAY 01, 1985

N62606 001

MAY 15, 1985

N60576 002

MAY 01, 1985

N62606 001

MAY 15, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

BARRE

100,000 UNITS/GM; 0.1%

N63010 001

DEC 20, 1988

N63010 001

DEC 20, 1988

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

B* NYSTATIN AND TRIAMCINOLONE ACETONIDE
CLAY PARK 100,000 UNITS/GM; 0.1%

@ 100,000 UNITS/GM; 0.1%

AT PHARMAFAIR 100,000 UNITS/GM; 0.1%

@ 100,000 UNITS/GM; 0.1%

OINTMENT; TOPICAL

AT MYCOLOG-II 100,000 UNITS/GM; 0.1%

AT WESTWOOD SQUIBB 100,000 UNITS/GM; 0.1%

AT NYSTATIN-TRIAMCINOLONE ACETONIDE
PHARMADERM 100,000 UNITS/GM; 0.1%

@ 100,000 UNITS/GM; 0.1%

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC

+ ASTRA MERCK 20MG

* MERCK 20MG

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M

@ 50MG
50MG

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAXIL

SMITHKLINE BEECHAM EQ 30MG BASE

N62186 002

JUN 06, 1985

N62186 002

JUN 06, 1985

N62657 001

JUL 30, 1986

N62657 001

JUL 30, 1986

N60572 001

JUN 28, 1985

N60572 001

JUN 28, 1985

N62603 001

OCT 09, 1985

N62603 001

OCT 09, 1985

N19810 001

SEP 14, 1989

N19810 001

SEP 14, 1989

N10653 001

N10653 001

N20031 003

DEC 29, 1992

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAXIL

+ SMITHKLINE BEECHAM EQ 30MG BASE

N20031 003
DEC 29, 1992

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

@ APOTHECON

1,000,000 UNITS/VIAL

5,000,000 UNITS/VIAL

10,000,000 UNITS/VIAL

20,000,000 UNITS/VIAL

1,000,000 UNITS/VIAL

5,000,000 UNITS/VIAL

10,000,000 UNITS/VIAL

20,000,000 UNITS/VIAL

N60362 001
N60362 003
N60362 004
N60362 002
N60362 001
N60362 003
N60362 004
N60362 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

BETAPEN-VK

@ APOTHECON

EQ 125MG BASE/SML

EQ 250MG BASE/SML

EQ 125MG BASE/SML

EQ 250MG BASE/SML

EQ 125MG BASE/SML

EQ 250MG BASE/SML

N61149 001
N61149 002
N61149 001
N61149 002
N61410 001
N61410 002

TABLET; ORAL

UTICILLIN VK

@ UPJOHN

EQ 500MG BASE

EQ 500MG BASE

N61651 002
N61651 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTACARINAT

+ RHONE POULENC RORER 300MG/VIAL

N73447 001
APR 28, 1994

PENTOBARBITAL SODIUM

CAPSULE; ORAL

PENTOBARBITAL SODIUM

<u>AA</u>	<u>50MG</u>	<u>N85937 001</u>	<u>100MG</u>	<u>N80857 002</u>
<u>AA</u>	<u>100MG</u>	<u>N85915 001</u>	<u>30MG</u>	<u>N80857 001</u>
		<u>N85937 001</u>	<u>30MG</u>	<u>N80857 001</u>
		<u>N85915 001</u>	<u>100MG</u>	<u>N80857 002</u>

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

DIPHENYLAN SODIUM

<u>BX</u>	<u>100MG</u>	<u>N80857 002</u>
		<u>N80857 001</u>
		<u>N80857 001</u>
		<u>N80857 002</u>

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

<u>AA</u>	<u>35MG</u>	<u>N85611 001</u>
<u>AA</u>	<u>35MG</u>	<u>N85611 001</u>

INJECTABLE; INJECTION

PHYTONADIONE

<u>EP</u>	<u>1MG/0.5ML</u>	<u>N84060 001</u>
<u>EP</u>	<u>10MG/ML</u>	<u>N84060 002</u>
		<u>N84060 001</u>
		<u>N84060 002</u>

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

<u>AA</u>	<u>30MG</u>	<u>N87022 001</u>
		<u>FEB 03, 1983</u>
		<u>N87022 001</u>
		<u>FEB 03, 1983</u>
		<u>N88613 001</u>
		<u>APR 09, 1984</u>
		<u>N88614 001</u>
		<u>APR 09, 1984</u>
		<u>N88613 001</u>
		<u>APR 09, 1984</u>
		<u>N88614 001</u>
		<u>APR 09, 1984</u>

TABLET; ORAL

SALAGEN

	<u>5MG</u>	<u>N20237 001</u>
		<u>MAR 22, 1994</u>

PILOCARPINE HYDROCHLORIDEPINDOLOL

TABLET; ORAL

PINDOLOL

<u>AB</u>	<u>5MG</u>	<u>N74063 001</u>
<u>AB</u>	<u>10MG</u>	<u>JAN 27, 1994</u>
		<u>N74063 002</u>
		<u>JAN 27, 1994</u>

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

<u>AA</u>	<u>5MG/5ML; 6.25MG/5ML</u>	<u>N88897 001</u>
		<u>JAN 04, 1985</u>
		<u>N88897 001</u>
		<u>JAN 04, 1985</u>

PIPERAZINE CITRATE

SYRUP; ORAL

BRYREL

	<u>EQ 500MG BASE/5ML</u>	<u>N17796 001</u>
		<u>N17796 001</u>
		<u>N80992 001</u>
		<u>N80992 001</u>

PIPERAZINE CITRATE

SYRUP; ORAL

BRYREL

	<u>EQ 500MG BASE/5ML</u>	<u>N17796 001</u>
		<u>N17796 001</u>
		<u>N80992 001</u>
		<u>N80992 001</u>

PIROXICAMCAPSULE; ORAL
PIROXICAM
NOVOPHARM10MGN73637 001
JAN 28, 1994
N73638 001
JAN 28, 199420MGPREDNISOLONETABLET; ORAL
PREDNISOLONE
@ ICN
BX INWOOD
@ INWOOD LABS
BX TABLICAPS
@5MG
5MG
5MG
5MGN80236 001
N80748 001
N80748 001
N85170 001
N85170 001PLICAMYCININJECTABLE; INJECTION
MITHRACIN
* WILLES
+ PFIZER2.5MG/VIAL
2.5MG/VIALN50109 001
N50109 001> DLT >
> DLT >
> ADD >
> ADD >N87771 001
AUG 06, 1993
N87771 001
AUG 06, 1993POLYMYXIN B SULFATEINJECTABLE; INJECTION
AEROSPORIN
* BURROUGHS WELLCOME500.000 UNITS/VIAL
EQ 500.000 U BASE/VIALN62036 001
N62036 001> ADD >
> ADD >
> DLT >
> DLT >N10210 002
N88791 001
OCT 05, 1984
N88791 001
OCT 05, 1984POLYMYXIN B SULFATEPFIZER
POLYMYXIN B SULFATE
PHARMA TEK500.000 UNITS/VIAL
EQ 500.000 U BASE/VIALN60716 001
N60716 001
N63000 001
SEP 30, 1994> DLT >
> DLT >
> ADD >
> ADD >N12813 002
N12813 002POTASSIUM CHLORIDEINJECTABLE; INJECTION
POTASSIUM CHLORIDE
FUSISANA2MEQ/MLN87885 001
FEB 03, 1983
N87885 001
FEB 03, 1983> ADD >
> DLT >
> DLT >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >N80751 002
N80751 002N80751 001
N80751 001PREDNISOLONETABLET; ORAL
PREDNISOLONE
BUNDY
@ ICN
BX5MG
5MG
5MGN88165 001
MAR 28, 1983
N88165 001
MAR 28, 1983
N40065 001
JUL 29, 1994PREDNISOLONE SODIUM PHOSPHATE
BAUSCH AND LOMB
EQ 0.11% PHOSPHATEEQ 0.9% PHOSPHATE
EQ 0.9% PHOSPHATEEQ 0.11% PHOSPHATE
EQ 0.11% PHOSPHATEEQ 0.9% PHOSPHATE
EQ 0.9% PHOSPHATE

PROPACARCAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

<u>AT</u>	<u>KAINAIR</u>	<u>0.5%</u>	<u>N88087 001</u>
	<u>PHARMFAIR</u>		<u>JUN 07, 1983</u>

@		<u>0.5%</u>	<u>N88087 001</u>
			<u>JUN 07, 1983</u>

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

<u>BD</u>	<u>DANBURY PHARMA</u>	<u>50MG</u>	<u>N80932 001</u>
	@	<u>50MG</u>	<u>N80932 001</u>
<u>BD</u>	<u>LANNETT</u>	<u>50MG</u>	<u>N80016 001</u>
	@	<u>50MG</u>	<u>N80016 001</u>
<u>BD</u>	<u>TABLICAPS</u>	<u>50MG</u>	<u>N80840 001</u>
	@	<u>50MG</u>	<u>N80840 001</u>

PROTIRELIN

INJECTABLE; INJECTION

RELEFACT TRH

<u>AP</u>	<u>FERRING LABS</u>	<u>0.5MG/ML</u>	<u>N18087 001</u>
	<u>THYREL TRH</u>		
<u>AP</u>	<u>FERRING LABS</u>	<u>0.5MG/ML</u>	<u>N18087 001</u>

PSEUDOEPHEDRINE HYDROCHLORIDE, TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

ALLERPED

PRIVATE FORM

<u>AA</u>		<u>60MG; 2.5MG</u>	<u>N88860 001</u>
	@	<u>60MG; 2.5MG</u>	<u>JAN 31, 1985</u>
		<u>60MG; 2.5MG</u>	<u>N88860 001</u>
			<u>JAN 31, 1985</u>

TRIPRED

LEMMON

<u>AA</u>		<u>60MG; 2.5MG</u>	<u>N88630 001</u>
	@	<u>60MG; 2.5MG</u>	<u>MAY 17, 1984</u>
		<u>60MG; 2.5MG</u>	<u>N88630 001</u>
			<u>MAY 17, 1984</u>

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

KALI DUPHAR

		<u>30MG</u>	<u>N89572 001</u>
			<u>NOV 27, 1990</u>

@	<u>SOLVAY</u>	<u>30MG</u>	<u>N89572 001</u>
			<u>NOV 27, 1990</u>

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDEX

<u>AB</u>	<u>ROBINS AH</u>	<u>300MG</u>	<u>N12796 002</u>
	@		
<u>AB</u>	<u>COPLY PHARM</u>	<u>300MG</u>	<u>N40045 001</u>
			<u>JUN 30, 1994</u>

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANTAC 150

GLAXO

		<u>EQ 150MG BASE</u>	<u>N20095 001</u>
			<u>MAR 08, 1994</u>

ZANTAC 300

+ GLAXO

		<u>EQ 300MG BASE</u>	<u>N20095 002</u>
			<u>MAR 08, 1994</u>

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

+ GLAXO

		<u>EQ 150MG BASE/PACKET</u>	<u>N20251 002</u>
			<u>MAR 31, 1994</u>

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

+ GLAXO

		<u>EQ 150MG BASE</u>	<u>N20251 001</u>
			<u>MAR 31, 1994</u>

RESERPINE

> DLT >
> DLT >
> DLT >
> ADD >

ELIXIR; ORAL

SERPASIL

CIBA

		<u>0.2MG/4ML</u>	<u>N09115 005</u>
		<u>0.2MG/4ML</u>	<u>N09115 005</u>

TABLET; ORAL

RESERPINE

EON LABS

> DLT >	<u>BP</u>	<u>0.25MG</u>	<u>N09838 002</u>
---------	-----------	---------------	-------------------

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

> ADD >	AA	200 uCi	N18671 002	> ADD >	
> ADD >			MAY 27, 1982	> ADD >	
> DLT >	AA	100 uCi	N18671 001	> DLT >	
> DLT >			MAY 27, 1982	> DLT >	
> DLT >	AA	200 uCi	N18671 002	> DLT >	
> DLT >			MAY 27, 1982		

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE

BRACCO DXS

SQUIBB

8-100 uCi	N10929 001
1-50mCi	N10929 003
8-100 uCi	N10929 001
1-50mCi	N10929 003

SOLUTION; ORAL

IODOTOPE

BRACCO DXS

SQUIBB

7-106mCi/BOT	N10929 002
7-106mCi/BOT	N10929 002

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

ABBOTT

@

50MG/VIAL	N18450 001
50MG/VIAL	N18450 001

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

@ BRACCO DXS

@ SQUIBB

1-8mCi/VIAL	N10927 001
1-8mCi/VIAL	N10927 001

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

BERLEX

120MG	N19865 005
-------	------------

	N19865 005
	APR 20, 1994

STANZOLOL

TABLET; ORAL

WINSTROL

+ SANOFI WINTHROP

2MG	
-----	--

* STERLING WINTHROP

2MG	
-----	--

> ADD >	
> ADD >	
> DLT >	
> DLT >	

N18671 002	
MAY 27, 1982	
N18671 001	
MAY 27, 1982	
N18671 002	
MAY 27, 1982	

N12885 001	
MAY 14, 1984	
N12885 001	
MAY 14, 1984	

STAVUDINE

CAPSULE; ORAL

ZERIT

@ BRISTOL MYERS SQUIBB 5MG

15MG	
------	--

20MG	
------	--

30MG	
------	--

40MG	
------	--

N20412 001	
JUN 24, 1994	
N20412 002	
JUN 24, 1994	
N20412 003	
JUN 24, 1994	
N20412 004	
JUN 24, 1994	
N20412 005	
JUN 24, 1994	

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

PFIZER

AP

50MG/VIAL	N18450 001
50MG/VIAL	N18450 001

EQ 1GM BASE/2ML	N60111 001
EQ 1GM BASE/2.5ML	N60111 001

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULF-10

CIBA VISION

ICLAS

SULFACETAMIDE SODIUM

PHARMAFAIR

@

SULFAIR FORTE

PHARMAFAIR

AT

> ADD >	AT
> DLT >	AT
> DLT >	AT
> DLT >	AT
> ADD >	AT
> ADD >	AT

N10927 001	
N10927 001	

10%	
10%	
10%	
10%	
30%	

N80025 001	
N80025 001	
N88947 001	
MAY 17, 1985	
N88947 001	
MAY 17, 1985	
N88385 001	
OCT 13, 1983	

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFAIR FORTE
@ PHARMAFAIR 30%N88385 001
OCT 13, 1983AT SULFAIR-15
PHARMAFAIR 15%N88186 001
MAY 25, 1983

15%

N88186 001
MAY 25, 1983SULFADIAZINE

TABLET; ORAL

AB + EON LABS 500MG

N40091 001
JUL 29, 1994

AB EON MANUFACTURE LABS 500MG

N40091 001
JUL 29, 1994

AB + LILLY 500MG

N04122 002

500MG

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

AB SULFAMETHOXAZOLE AND TRIMETHOPRIM
FUJISAWA 80MG/ML; 16MG/MLN70223 001
DEC 29, 1987

80MG/ML; 16MG/ML

N70223 001
DEC 29, 1987

SUSPENSION; ORAL

AB BACTRIM
+ ROCHE

200MG/5ML; 40MG/5ML

200MG/5ML; 40MG/5ML

AB BACTRIM PEDIATRIC
ROCHE

200MG/5ML; 40MG/5ML

200MG/5ML; 40MG/5ML

AB TRIMETH/SULFA
BARRE

200MG/5ML; 40MG/5ML

200MG/5ML; 40MG/5ML

200MG/5ML; 40MG/5ML

TABLET; ORAL

AB SULFAMETHOXAZOLE AND TRIMETHOPRIM
EON LABS 400MG; 80MGN18598 003
MAY 19, 1982SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

AB SULFAMETHOXAZOLE AND TRIMETHOPRIM
@ EON LABS 400MG; 80MGN18598 003
MAY 19, 1982AB UROPLUS DS
SHIONOGI 800MG; 160MGN71816 001
SEP 28, 1987

@ 800MG; 160MG

N71816 001
SEP 28, 1987AB UROPLUS SS
SHIONOGI 400MG; 80MGN71815 001
SEP 28, 1987

@ 400MG; 80MG

N71815 001
SEP 28, 1987SULFASALAZINE

SUSPENSION; ORAL

* KABI AZULFIDINE

250MG/5ML

250MG/5ML

250MG/5ML

N18605 001

N86983 001

N18605 001

N86983 001

@ PHARMACIA

+

SULFISOXAZOLE

TABLET; ORAL

AB SULFISOXAZOLE
LANNETT 500MGN80085 001
N80085 001TACROLIMUS

CAPSULE; ORAL

+ FUJISAWA

EQ 1MG BASE

N50708 001
APR 08, 1994

EQ 5MG BASE

N50708 002
APR 08, 1994

INJECTABLE; INJECTION

+ FUJISAWA

EQ 5MG BASE/ML

N50709 001
APR 08, 1994

TALBUTALTALBUTAL; ORAL

> ADD >
> DLT >
LOTUSATE
@ SANOFI WINTHROP 120MG
@ STERLING WINTHROP 120MG

N09410 005
N09410 005
N19785 001
DEC 21, 1990
N19785 001
DEC 21, 1990
N/A
N/A

TAMOXIFEN CITRATETALBUTAL; ORAL

> DLT >
> DLT >
> ADD >
> ADD >
NOLVADEX
* ZENECA
EQ 20MG BASE
EQ 20MG BASE

N17970 002
MAR 21, 1994
N17970 002
MAR 21, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KITINJECTABLE; INJECTION

MACROTEC
BRACCO DXS
SQUIBB

N17833 001
N17833 001

N16923 001
N16923 001

TECHNETIUM TC-99M FERMENTETATE KITINJECTABLE; INJECTION

RENOTEC
@ BRACCO DXS
@ SQUIBB

N17045 001
N17045 001

N50263 002
N60400 001
N60633 001
N60174 001
N60291 001
N60895 001
N61468 001

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION

MDP-SQUIBB
BRACCO DXS
SQUIBB

N18107 001
N18107 001

TECHNETIUM TC-99M OXIDRONATE KITINJECTABLE; INJECTION

OSTEOSCAN-HDP
MALLINCKRODT
TECHNISCAN HDP
MALLINCKRODT

N18321 001
N18321 001

N60471 002
N60471 002

N50653 001
MAR 25, 1994

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION

CARDIOLITE
DUPONT
DUPONT MERCK

N19785 001
DEC 21, 1990
N19785 001
DEC 21, 1990
N/A
N/A

TECHNETIUM TC-99M SULFUR COLLOID KITSOLUTION; INJECTION, ORAL

TESULOID
SQUIBB

N16923 001

SOLUTION; INTRAVENOUS, ORAL

TESULOID
BRACCO DXS

N16923 001

TETRACYCLINESYRUP; ORALACHROMYCIN VLEDERLESUMYCINSQUIBBTETRACYCLINEBARREMKTETRACYCLINE HCLPUREPACTETRACYNPFIPHARMCECSTETRAMEDZENITH

EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML
EQ 125MG HCL/5ML

TETRACYCLINE HYDROCHLORIDECAPSULE; ORALTETRACYCLINE HCLICN@500MG500MG

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
+ ON SITE

12.7MG/FIBER

TETRACYCLINE HYDROCHLORIDE

SYRUP; ORAL	
<u>ACHROMYCIN V</u>	
AB + LEDERLE	125MG/5ML
AB SUMYCIN	125MG/5ML
AB SQUIBB	125MG/5ML
<u>TETRACYCLINE HCL</u>	
AB BARRE	125MG/5ML
AB MK LABS	125MG/5ML
AB PUREPAC PHARM	125MG/5ML
<u>TETRACYN</u>	
AB PFIPHARMECS	125MG/5ML
AB TETRAMED	125MG/5ML
AB ZENITH LABS	125MG/5ML
TABLET; ORAL	
<u>PANMYCIN</u>	
AB UPJOHN	500MG
AB @	250MG
AB @	500MG
<u>SUMYCIN</u>	
AB * APOTHECON	500MG
AB +	500MG

TABLET; ORAL

PANMYCIN

AB UPJOHN

AB @

AB @

SUMYCIN

AB * APOTHECON

AB +

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL	
TYZINE	
+ KENWOOD LABS	0.05%
* KEY PHARMS	0.1%
* KEY PHARMS	0.05%
* KEY PHARMS	0.1%
SPRAY; NASAL	
TYZINE	
+ KENWOOD LABS	0.1%
* KEY PHARMS	0.1%
<u>THEOPHYLLINE</u>	
CAPSULE, EXTENDED RELEASE; ORAL	
<u>SLO-BID</u>	
AB RHONE POULENC RORER	100MG
AB	125MG

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

SLO-BID

AB RHONE POULENC RORER

AB 200MG

AB +

AB 300MG

THEOPHYLLINE

AB INWOOD LABS

AB 100MG

AB 125MG

AB 200MG

AB 300MG

AB

ELIXIR; ORAL

LANOPHYLLIN

AA LANNETT

AA @

THEOPHYLLINE

AA BARRE

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

AA @

> ADD >
> ADD >
> DLT >
> DLT >

> ADD >
> DLT >

SYRUP; ORAL
ACCURON
MERRELL DOW
@
N87892 001
JAN 31, 1985
N89540 001
MAY 10, 1989

N87893 001
JAN 31, 1985
N87894 001
JAN 31, 1985
N40052 001
FEB 14, 1994
N40052 002
FEB 14, 1994
N40052 003
FEB 14, 1994
N40052 004
FEB 14, 1994
N84578 001
N84578 001
N89223 001
MAY 27, 1988
N89223 001
MAY 27, 1988
N87679 001
APR 15, 1982
N87679 001
APR 15, 1982

80MG/15ML
80MG/15ML
80MG/15ML
80MG/15ML
80MG/15ML
80MG/15ML
80MG/15ML

INJECTABLE; INJECTION
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP MCGAW
N19212 003
NOV 07, 1984
AP BAXTER
N18649 007
JUL 26, 1982
AP ABBOTT
N19211 007
DEC 14, 1984

SYRUP; ORAL

SLO-BID

AB RHONE POULENC RORER

AB 100MG

AB 125MG

AB

N88746 001
NOV 22, 1985
N88746 001
NOV 22, 1985

150MG/15ML
150MG/15ML

THEOPHYLLINE

SYRUP, ORAL

AA THEOPHYLLINE

PARRE

®

80MG/15ML
80MG/15MLN86001 001
N86001 001> ADD >
> ADD >
> ADD >
> ADD >EQ 40MG BASE/ML

N63121 001

OCT 31, 1994

EQ 40MG BASE/ML

N63122 001

OCT 31, 1994

THYROGLOBULIN

TABLET; ORAL

PROLOID

BP * PARKE DAVIS

65MG
32MG

100MG

130MG

200MG

32MG

65MG

100MG

130MG

200MG

THYROGLOBULIN

+ GLOBAL PHARMS

RICHLYN

64.8MG

N80151 001

N80151 001

BP

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

STERIS

0.3%

N63176 001

MAY 25, 1994

AT

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

APOTHECON

EQ 10MG BASE/ML

N64021 001

MAY 31, 1994

AT

EQ 40MG BASE/ML

N64021 002

MAY 31, 1994

AT

EQ 40MG BASE/ML

N64026 001

MAY 31, 1994

AT

EQ 10MG BASE/ML

N63119 001

OCT 31, 1994

AT

EQ 40MG BASE/ML

N63120 001

OCT 31, 1994

AT

> ADD >
> ADD >
> ADD >
> ADD >TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

ASTRA

EQ 40MG BASE/ML

N63121 001

OCT 31, 1994

EQ 40MG BASE/ML

N63122 001

OCT 31, 1994

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC

CONTAINER

+ ABBOTT

EQ 1.6MG BASE/ML

N63081 006

JUN 02, 1993

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

MYLAN

EQ 600MG BASE

N74473 001

AUG 30, 1994

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

MYLAN

2MG

N84406 001

N84406 001

BP

TRIAMCINOLONE ACETONIDE

AEROSOL; TOPICAL

KENALOG

+ APOTHECON

+ WESTWOOD SQUIBB

0.147MG/GM

0.147MG/GM

N12104 001

N12104 001

CREAM; TOPICAL

KENALOG

+ APOTHECON

0.025%

0.1%

0.5%

0.025%

0.1%

0.5%

0.025%

0.1%

0.5%

TRIAMCINOLONE ACETONIDE

TARO PHARMS

0.025%

N40038 001

OCT 26, 1994

TRIAMCINOLONE ACETONIDE

AT OINTMENT; TOPICAL
AT KENALOG
AT + APOTHECON 0.025%
AT + 0.1%
AT + 0.5%
AT WESTWOOD SQUARE 0.025%
AT + 0.1%
AT + 0.5%
AT TRIAMCINOLONE ACETONIDE
AT TARO PHARMS 0.025%
AT 0.1%

TRILOSTANE

CAPSULE; ORAL
 MODRASTANE
 SANOFI WINTHROP 30MG N18719 002
 DEC 31, 1984
 + 60MG N18719 001
 DEC 31, 1984
 STERLING WINTHROP 30MG N18719 002
 DEC 31, 1984
 * 60MG N18719 001
 DEC 31, 1984
 N40040 001
 SEP 30, 1994
 N40037 001
 SEP 30, 1994

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

SUSPENSION; ORAL
 LANTRISUL
 LANNEBT 167MG/5ML; 167MG/5ML; N80123 002
 167MG/5ML
 @ 167MG/5ML; 167MG/5ML; N80123 002
 167MG/5ML

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
 MYDRIAPAIR
 PHARMAFAIR 0.5% N88274 001
 SEP 16, 1983
 1% N88230 001
 SEP 16, 1983
 @ 0.5% N88274 001
 SEP 16, 1983
 @ 1% N88230 001
 SEP 16, 1983
 TROPICAMIDE
 BAUSCH AND LOMB 0.5% N40067 001
 JUL 27, 1994
 1% N40064 001
 JUL 27, 1994

TRIHENYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 ARTANE
 * LEADERLE 5MG
 5MG
 @ 5MG
 + 5MG

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 ISOPTIN SR
 AB + KNOLL PHARM 180MG N19152 002
 DEC 15, 1989

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

BAKER NORTON

180MG

N74330 001
JAN 31, 1994

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

BULL

10MG/VIAL

N89565 001

AP

AUG 18, 1987

AP FAULDING

10MG/VIAL

N89565 001

AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

FUJISAWA

1MG/ML

N70411 001

@

1MG/ML

SEP 10, 1986

N70411 001

SEP 10, 1986

VINCRISTINE SULFATE PFS

BULL

1MG/ML

N71484 001

AP

APR 19, 1988

AP FAULDING

1MG/ML

N71484 001

APR 19, 1988

ACETAMINOPHEN

SUPPOSITORY; RECTAL
INFANTS' FEVERALL
UPSHER SMITH

80MG

N18337 004
AUG 26, 1992

TABLET, EXTENDED RELEASE; ORAL
TYLENOL

+ MCNEIL CONS PRODS

650MG

N19872 001
JUN 08, 1994

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
COMBE

500 UNITS/GM

N62799 001
MAY 14, 1987
N62799 001
MAY 14, 1987

500 UNITS/GM

N62799 001
MAY 14, 1987

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MYCELEX-7 COMBINATION PACK
MILES

1%, 100MG

N20389 002
JUN 23, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
BARRE

12.5MG/5ML

N70497 001
APR 25, 1989
N70497 001
APR 25, 1989

12.5MG/5ML

IBUPROFEN

TABLET; ORAL
IBUPROFEN
MCNEIL CONS PRODS

200MG

N73019 001
MAR 30, 1994
N73691 001
FEB 25, 1994

200MG

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN BR
* LILLY

100 UNITS/ML

N19529 001
APR 28, 1986
N19529 001
APR 28, 1986

@

100 UNITS/ML

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
* NOVIO NORDISK

40 UNITS/ML

N17929 001
N17929 001

@

40 UNITS/ML

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION
NPH Iletin I (BEEF-PORK)
* LILLY

40 UNITS/ML

N17936 001
N17936 001

@

40 UNITS/ML

> DLT >
> ADD >

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
NAPHCON-A
+ ALCON

0.025%; 0.3%

N20226 001
JUN 08, 1994

OPCON-A

+ BAUSCH AND LOMB

0.027%; 0.315%

N20065 001
JUN 08, 1994

NAPROXEN SODIUM

TABLET; ORAL
ALEVE

HAMILTON PHARMS

EQ 200MG BASE

N20204 002
JAN 11, 1994

PERMETHRIN

LOTION; TOPICAL

NIX

* BURROUGHS WELLCOME 1%

+ WARNER WELLCOME 1%

N19918 001
MAY 02, 1990
N19918 001
MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC/24

+ CIBA CONS 240MG

N20021 002
DEC 15, 1992

PSEUDOEPHEDRINE HCL
ALZA 240MG

N20021 002
DEC 15, 1992

SUDAFED 12 HOUR

* BURROUGHS WELLCOME 120MG

N73585 001
OCT 31, 1991

+ WARNER WELLCOME 120MG

N73585 001
OCT 31, 1991

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 10 / OCTOBER '94

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION	
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER	N940404
BAXTER HLTHCARE	JUL 28, 1994

INDIUM IN ¹¹¹ CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION	
ULTRAPURE	N19841
MALLINCKRODT	SEP 27, 1994
N/A	

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January-October, 1994]

NAME <i>Generic/Chemical</i> <i>TN= Trade Name</i>	INDICATION DESIGNATED	SPONSOR & ADDRESS <i>DD=Date Designated</i> <i>MA=Marketing Approval</i>
8-METHOXSALEN TN= UVADEX	FOR THE PREVENTION OF ACUTE REJECTION OF CARDIAC ALLOGRAFTS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 05/12/94 MA / /
AMINOSALICYLIC ACID TN= PASER GRANULES	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY 37 CLEVELAND LANE PRINCETON NJ 08540 DD 02/19/92 MA 06/30/94
AMINOSIDINE TN= PAROMOMYCIN	TREATMENT OF VISCERAL LEISHMANIASIS (KALA-AZAR).	KANYOK, THOMAS P. PHARM.D. UNIV. OF ILLINOIS AT CHICAGO CHICAGO IL 60612 DD 09/09/94 MA / /
AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA / /
AMMONIUM TETRATHIOMOLYBDATE TN=	TREATMENT OF WILSON'S DISEASE.	BREWER, GEORGE J. M.D. UNIVERSITY OF MICHIGAN MEDICAL SCHOOL ANN ARBOR MI 48109-0618 DD 01/31/94 MA / /
ANTIVENIN, POLYVALENT CROTALID (OVINE) FAB TN= CROTAB	TREATMENT OF ENVENOMATIONS INFLICTED BY NORTH AMERICAN CROTALID SNAKES.	THERAPEUTIC ANTIBODIES INC. 1500 21ST AVENUE SOUTH, SUITE 310 NASHVILLE TN 37212 DD 01/12/94 MA / /
ARGININE BUTYRATE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
AUTOLYMPHOCYTE THERAPY TN=	TREATMENT OF RENAL CELL CARCINOMA.	CELLCOR INCORPORATED 200 WELLS AVENUE NEWTON MA 02159 DD 07/12/94 MA / /
BACLOFEN TN= LIORESAL INTRATHECAL	TREATMENT OF SPASTICITY ASSOCIATED WITH CEREBRAL PALSY.	MEDTRONIC, INCORPORATED 800 53RD AVENUE N.E. MINNEAPOLIS MN 55432 DD 09/26/94 MA / /
BETAINE TN=	TREATMENT OF HOMOCYSTEINURIA.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 05/16/94 MA / /
BOVINE IMMUNOGLOBULIN CONCENTRATE, CRYPTOSPORIDIUM PARVUM TN= SPORIDIN-G	TREATMENT AND SYMPTOMATIC RELIEF OF CRYPTOSPORIDIUM PARVUM INFECTION OF THE GASTROINTESTINAL TRACT IN IMMUNOCOMPROMISED PATIENTS.	GALAGEN, INCORPORATED 4001 LEXINGTON AVENUE NORTH ARDEN HILLS MN 55126-2998 DD 03/01/94 MA / /
BUPRENORPHINE HYDROCHLORIDE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS, INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 06/15/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
BUPRENORPHINE IN COMBINATION WITH NALOXONE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 10/27/94 MA / /
BUSULFAN TN=	FOR USE AS PREPARATIVE THERAPY FOR MALIGNANCIES TREATED WITH BONE MARROW TRANSPLANTATION.	SPARTA PHARMACEUTICALS, INC. P.O. BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 04/21/94 MA / /
BUSULFAN TN=	AS PREPARATIVE THERAPY IN THE TREATMENT OF MALIGNANCIES WITH BONE MARROW TRANSPLANTATION.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 07/28/94 MA / /
CCD 1042 TN=	TREATMENT OF INFANTILE SPASMS.	COCENSYS, INC. 213 TECHNOLOGY DRIVE IRVINE CA 92718 DD 05/25/94 MA / /
CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MAB TO CD20 TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 06/13/94 MA / /
CHOLINE CHLORIDE TN=	TREATMENT OF CHOLINE DEFICIENCY, SPECIFICALLY THE CHOLINE DEFICIENCY, HEPATIC STEATOSIS, AND CHOLESTASIS, ASSOCIATED WITH LONG-TERM PARENTERAL NUTRITION.	BUCHMAN, ALAN M.D. 6550 FANNIN, SUITE 1122 HOUSTON TX 77030 DD 02/10/94 MA / /
CLADRIBINE TN= LEUSTATIN	TREATMENT OF THE CHRONIC PROGRESSIVE FORM OF MULTIPLE SCLEROSIS.	R.W. JOHNSON RESEARCH INSTITUTE 700 ROUTE 200 SOLUTH, P.O. BOX 670 RARITAN NJ 08869-0670 DD 04/19/94 MA / /
CLONAZEPAM TN= KLOPIN	TREATMENT OF HYPEREKPLEXIA (STARTLE DISEASE).	HOFFMAN-LA ROCHE, INCORPORATED 340 KINGSLAND STREET NUTLEY NJ 07110-1199 DD 08/04/94 MA / /
COAGULATION FACTOR IX (RECOMBINANT) TN=	TREATMENT OF HEMOPHILIA B.	GENETICS INSTITUTE, INCORPORATED 87 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 DD 10/03/94 MA / /
CY-1899 TN=	TREATMENT OF CHRONIC ACTIVE HEPATITIS B INFECTION IN HLA-A2 POSITIVE PATIENTS.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 03/16/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
CYSTEAMINE TN= CYSTAGON	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	MYLAN LABORATORIES, INC 781 CHESTNUT RIDGE ROAD, PO BOX 4310 MORGANTOWN WV 26504-4310 DD 01/25/91 MA 08/15/94
DEHYDROEPIANDROSTERONE TN=	TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND THE REDUCTION IN THE USE OF STEROIDS IN STEROID-DEPENDENT SLE PATIENTS.	GENELABS TECHNOLOGIES, INC. 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 DD 07/13/94 MA / /
DESMOPRESSIN ACETATE TN=	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD COLLEGEVILLE PA 19426 DD 01/22/91 MA 03/07/94
ELLIOTT'S B SOLUTION TN=	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIAS AND ACUTE LYMPHOBLASTIC LYMPHOMAS.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 08/24/94 MA / /
FGN-1 TN=	FOR THE SUPPRESSION AND CONTROL OF COLONIC ADENOMATOUS POLYPS IN THE INHERITED DISEASE ADENOMATOUS POLYPOSIS COLI.	CELL PATHWAYS, INC. 1700 BROADWAY, SUITE 2000 DENVER CO 80290 DD 02/14/94 MA / /
GAMMALINOLENIC ACID TN=	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	ZURIER, ROBERT B. M.D. 55 LAKE AVE. UNIV. OF MASS. MED. CTR. WORCESTER MA 01655 DD 07/27/94 MA / /
HEME ARGINATE TN= NORMOSANG	TREATMENT OF MYELOYDPLASTIC SYNDROMES.	LEIRAS, INCORPORATED 1850 CENTENNIAL PARK DRIVE, SUITE 450 RESTON VA 22091 DD 03/01/94 MA / /
I-131 RADIOLABELED B1 MONOCLONAL ANTIBODY TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	COULTER CORPORATION 11800 S.W. 147 AVENUE, P.O. BOX 169015 MIAMI FL 33116-9015 DD 05/16/94 MA / /
IN-111 MURINE MAB(2B8-MX-DTPA) & Y-90 MURINE MAB(2B8-MXDTPA) TN= MELIMMUNE	TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 09/06/94 MA / /
IMIGLUCERASE TN= CEREZYME	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139 DD 11/05/91 MA 05/23/94
ISOBUTYRAMIDE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID TN= PROCYSTEINE	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	FREE RADICAL SCIENCES, INC. 245 FIRST STREET CAMBRIDGE MA 02142 DD 06/14/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
L-CYSTEINE TN=	FOR THE PREVENTION AND LESSENING OF PHOTSENSITIVITY IN ERYTHROPOIETIC PROTOPORPHYRIA.	TYSON AND ASSOCIATES 12832 SOUTH CHADRON AVENUE HAWTHORNE CA 90250 DD 05/16/94 MA / /
LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TN=	TREATMENT OF CANCERS OF THE KIDNEY AND RENAL PELVIS.	ONCOTHERAPEUTICS, INC. 1002 EASTPARK BOULEVARD CRANBURY NJ 08512 DD 06/20/94 MA / /
MELANOMA CELL VACCINE TN=	TREATMENT OF INVASIVE MELANOMA.	MORTON, DONALD L. M.D. JOHN WAYNE CANCER INSTITUTE SANTA MONICA CA 90404 DD 10/13/94 MA / /
MITOGUAZONE TN=	TREATMENT OF DIFFUSE NON-HODGKIN'S LYMPHOMA, INCLUDING AIDS-RELATED DIFFUSE NON-HODGKIN'S LYMPHOMA.	CTRC RESEARCH FOUNDATION 11812 BECKET STREET POTOMAC MD 20854 DD 03/18/94 MA / /
MONOCLONAL AB(MURINE) ANTI-IDIOTYPE MELANOMA ASS'TED ANTIGEN TN= MELIMMUNE	TREATMENT OF INVASIVE CUTANEOUS MELANOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 09/19/94 MA / /
N-TRIFLUOROACETYLADRIAMYCIN-14-V ALERATE TN=	TREATMENT OF CARCINOMA IN SITU OF THE URINARY BLADDER.	ANTHRA PHARMACEUTICALS, INC. 19 CARSON ROAD PRINCETON NJ 08540 DD 05/23/94 MA / /
NEUROTROPHIN-1 TN=	TREATMENT OF MOTOR NEURON DISEASE/AMYOTROPHIC LATERAL SCLEROSIS.	ERICSSON, ARTHUR DALE, M.D. 6560 FANNIN, SCURLOCK TOWER, SUITE 720 HOUSTON TX 77303 DD 09/13/94 MA / /
OXANDROLONE TN= HEPANDRIN	TREATMENT OF MODERATE/SEVERE ACUTE ALCOHOLIC HEPATITIS IN THE PRESENCE OF MODERATE PROTEIN CALORIE MALNUTRITION.	BIO-TECHNOLOGY GENERAL CORP. 70 WOOD AVENUE SOUTH ISELIN NJ 08830 DD 03/18/94 MA / /
PEGASPARGASE TN= ONCASPAR	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL).	ENZON, INC. 40 KINGSBRIDGE ROAD PISCATAWAY NJ 08854-3998 DD 10/20/89 MA 02/01/94
PILOCARPINE TN= SALAGEN	TREATMENT OF XEROSTOMIA INDUCED BY RADIATION THERAPY FOR HEAD AND NECK CANCER.	MGI PHARMA, INC. SUITE 300 E, 9900 BREN ROAD EAST MINNEAPOLIS MN 55343-9667 DD 09/24/90 MA 03/22/94
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF THE RESPIRATORY SYMPTOMS OF CYSTIC FIBROSIS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02124 DD 01/12/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
RECOMBINANT HUMAN LUTEINIZING HORMONE TN=	FOR USE IN ASSOCIATION WITH RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE FOR THE TREATMENT OF WOMEN WITH CHRONIC ANOVULATION DUE TO HYPOGONADOTROPIC HYPOGONADISM.	SERONO LABORATORIES, INCORPORATED 100 LONGWATER CIRCLE NORWELL MA 02061 DD 10/07/94 MA / /
RECOMBINANT VACCINIA (HUMAN PAPILLOMAVIRUS) TN= TA-HPV	TREATMENT OF CERVICAL CANCER.	CANTAB PHARMACEUTICALS RESEARCH, LTD. 184 CAMBRIDGE SCIENCE PARK CAMBRIDGE CB4 4GN UK DD 08/24/94 MA / /
REDUCED L-GLUTATHIONE TN= CACHEXON	TREATMENT OF AIDS-ASSOCIATED CACHEXIA.	TELLURIDE PHARMACEUTICAL CORPORATION 146 FLANDERS DRIVE HILLSBOROUGH NJ 08876-4656 DD 02/14/94 MA / /
RICIN (BLOCKED) CONJUGATED MURINE MOAB (CD6) TN=	TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS, ACUTE T-CELL LEUKEMIA-LYMPHOMA, AND RELATED MATURE T-CELL MALIGNANCIES.	IMMUNOGEN, INC. 148 SIDNEY STREET CAMBRIDGE MA 02139-4239 DD 09/06/94 MA / /
RIFAMPIN, ISONIAZID, PYRAZINAMIDE TN= RIFATER	SHORT-COURSE TREATMENT OF TUBERCULOSIS.	MARION MERRELL DOW, INC. P.O. BOX 9627 KANSAS CITY MO 64134-0627 DD 09/12/85 MA 05/31/94
SOMATROPIN TN= GENOTROPIN/GENOTONORM	TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 09/06/94 MA / /
SOMATROPIN TN= NUTROPIN (EXCLUSIVITY NOT APPLICABLE)	FOR USE IN THE LONG-TERM TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE DUE TO A LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 03/06/87 MA 03/09/94
SULFADIAZINE TN=	FOR USE IN COMBINATION WITH PYRIMETHAMINE FOR THE TREATMENT OF TOXOPLASMA GONDII ENCEPHALITIS IN PATIENTS WITH AND WITHOUT ACQUIRED IMMUNODEFICIENCY SYNDROME.	EON LABS MANUFACTURING, INC. 227-15 NORTH CONDUIT AVENUE LAURELTON NY 11413 DD 03/14/94 MA 07/29/94
TIZANIDINE HCL TN= ZANAFLEX	TREATMENT OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS AND SPINAL CORD INJURY.	ATHENA NEUROSCIENCES, INC. 800F GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/31/94 MA / /
TOBRAMYCIN FOR INHALATION TN=	TREATMENT OF BRONCHOPULMONARY INFECTIONS OF PSEUDOMONAS AERUGINOSA IN CYSTIC FIBROSIS PATIENTS.	PATHOGENESIS CORPORATION 201 ELLIOTT AVENUE WEST, SUITE 150 SEATTLE WA 98119 DD 10/13/94 MA / /
TREOSULFAN TN= OVASTAT	TREATMENT OF OVARIAN CANCER.	MEDAC GmbH c/o PRINCETON REG. ASSOC. 65 SOUTH MAIN STREET PENNINGTON NJ 08534 DD 05/16/94 MA / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1994 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
-------------------------	------	--------------

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ALBUTEROL (METERED DOSE INHALER - <i>IN VIVO</i>)	JAN 27, 1994	
DICLOFENAC SODIUM (TABLET)	DEC 24, 1992	OCT 06, 1994
FLURBIPROFEN (TABLET)	DEC 24, 1992	FEB 04, 1994
PHENYTOIN (SUSPENSION AND CHEWABLE TABLET)	MAR 04, 1994	
PHENYTOIN SODIUM (CAPSULE, EXTENDED AND PROMPT)	MAR 04, 1994	
TOLMETIN SODIUM (CAPSULE AND TABLET)	APR 20, 1989	OCT 06, 1994

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
---------------------------------	------------------------------	---------------	------------	------------------------	--------

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ACYCLOVIR TABLET; ORAL	200MG	93 P-0339/ CP1	NOVOPHARM	NEW DOSAGE FORM	APPROVED FEB 08, 1994
ACYCLOVIR SODIUM INJECTABLE; INJECTION	25MG/ML (20ML/VIAL) (40ML/VIAL)	93 P-0469/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUN 09, 1994
ESTRADIOL TABLET; ORAL	1.5MG	93 P-0344/ CP1	BRISTOL MYERS SQIBB	NEW STRENGTH	APPROVED JUN 08, 1994
LOPERAMIDE HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	1MG	93 P-0332/ CP1	ELLIS PHARM CONSULTING	NEW DOSAGE FORM	APPROVED FEB 08, 1994
METHYLTESTOSTERONE CAPSULE; ORAL	25MG	93 P-0459/ CP1	ICN	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	15MG 60MG 100MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	90MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 08, 1994
PREDNISONE TABLET, CHEWABLE; ORAL	1MG 2.5MG 20MG 50MG	93 P-0333/ CP1	DURA	NEW DOSAGE FORM	APPROVED JUN 08, 1994
PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE CAPSULE, EXTENDED RELEASE; ORAL	120MG 60MG	93 P-0367/ CP1	EURAND AMERICA	NEW DOSAGE FORM	APPROVED FEB 08, 1994

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
---------------------------------	------------------------------	---------------	------------	------------------------	--------

ERRATA

CIMETIDINE TABLET, EFFERVESCENT; ORAL	200MG 300MG 400MG 800MG	93 P-0048/ CP1*	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED SEP 18, 1993
--	----------------------------------	--------------------	------------------	--------------------	--------------------------

*Not previously published

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

- D-21 ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
- D-22 REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
- D-23 INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
- D-24 FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M² OR 175MG/M² INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
- D-25 ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF OF THE ORIGINAL DOSING REGIMEN

REFERENCES

NEW INDICATION

- I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
- I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
- I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
- I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
- I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
- I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
- I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
- I-106 TREATMENT OF ACROMEGALY
- I-107 VAGINAL CANDIDIASIS
- I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
- I-109 TYPHOID FEVER
- I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
- I-111 TREATMENT OF PAGET'S DISEASE OF BONE
- I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN

REFERENCES

PATENT USE CODE

- U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
- U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
- U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT
- U-94 TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
- U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
- U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
- U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
- U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19872 001	ACETAMINOPHEN; TYLENOL	4650807	MAR 17, 2004	U-93	NDF	JUN 08, 1997
19806 001	ACRIVASTINE; SEMPRES-D	4501893	FEB 26, 2002		NC	MAR 25, 1997
74346 001	AMINOSALICYLIC ACID; PASER				ODE	JUN 30, 2001
18700 001	AMRINONE LACTATE; INOCOR	4072746	JUL 31, 1998	U-7	NCE	JUL 31, 1994
20304 001	APROTININ BOVINE; TRASYLOL				ODE	DEC 29, 2000
					D-25	OCT 12, 1997
18831 001	ATRACURIUM BESYLATE; TRACRIUM	4179507	DEC 18, 1996		I-108	JUN 06, 1997
20233 001	BUDESONIDE; RHINOCORT				NCE	FEB 14, 1999
18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
18343 001	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 002	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 003	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 005	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 006	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-101	JAN 28, 1997
					I-95	SEP 23, 1996
19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
					I-109	JUL 21, 1997
19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
					I-109	JUL 21, 1997
19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
					I-109	JUL 21, 1997
20392 001	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
20392 002	CYSTEAMINE BITARTRATE; CYSTAGON				ODE	AUG 15, 2001
					NCE	AUG 15, 1999
20355 001	DESMOPRESSIN ACETATE; DESMOPRESSIN ACETATE				ODE	AUG 15, 2001
					NP	MAR 07, 1997
					ODE	MAR 07, 2001
20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	JUL 26, 2000	U-95		
81295 001	ESTRADIOL; ESTRACE				NDF	APR 01, 1997
20323 001	ESTRADIOL; VIVELLE				I-76	SEP 08, 1995
20323 003	ESTRADIOL; VIVELLE				NS	OCT 28, 1997
					NS	OCT 28, 1997

>ADD>

>ADD>

>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
18922 004	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45	NCE	JAN 31, 1996
20363 002	FAMCICLOVIR; FAWVIR	5246937	SEP 21, 2010	U-96	NCE	JUN 29, 1999
20249 001	FAMOTIDINE; PEPICID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
19834 004	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
19304 001	FENOFIBRATE; LIPIDIL	4058552	NOV 15, 1994		NCE	DEC 31, 1998
19960 001	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
19960 002	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
19960 003	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
19960 004	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
19950 001	FLUCONAZOLE; DIFLUCAN	4552884	NOV 12, 2002		I-100	DEC 30, 1996
20322 001	FLUCONAZOLE; DIFLUCAN	4302460	NOV 24, 1998		NCE	JAN 29, 1995
					NS	JUN 30, 1997
					I-107	JUN 30, 1997
18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4018895	APR 19, 1994	U-12	I-102	FEB 28, 1997
18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
20235 001	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
20235 002	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
20235 003	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
20123 001	GADODIAMIDE; OMNISCAN	4687659	JAN 08, 2007	U-76	NCE	JAN 08, 1998
20329 001	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
20329 002	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
19778 003	HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5					
19888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-12.5	4472380	SEP 18, 2001	U-3	NS	NOV 18, 1996
		4374829	DEC 30, 2001			
		4472380	SEP 18, 2001			
		4374829	DEC 30, 2001	U-3		
19888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-25	4374829	DEC 30, 2001	U-3		
19888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5	4472380	SEP 18, 2001		NS	NOV 18, 1996
		4374829	DEC 30, 2001	U-3		
19771 001	IBUPROFEN; ADVIL COLD AND SINUS					
20367 001	IMIGLUCERASE; CEREZYME	4552899	NOV 12, 2002		NCE	MAY 23, 1999
					ODE	MAY 23, 2001
					NCE	JUN 02, 1999
20314 001	INDIUM IN-111 PENTETROTIDE KIT; OCTREOSCAN					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131	4584187	APR 22, 2003		NCE	MAR 25, 1999
50705 001	ISONIAZID; RIFATER				ODE	MAY 31, 2001
20336 001	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
		4950486	AUG 21, 2007		NDF	JUN 01, 1997
		4946687	AUG 07, 2007		NCE	DEC 20, 1995
		4816263	MAR 28, 2006	U-3		
		4783337	SEP 16, 2003	U-3		
		4466972	AUG 21, 2003	U-3		
20336 002	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
		4950486	AUG 21, 2007		NDF	JUN 01, 1997
		4946687	AUG 07, 2007		NCE	DEC 20, 1995
		4816263	MAR 28, 2006	U-3		
		4783337	SEP 16, 2003	U-3		
		4466972	AUG 21, 2003	U-3		
20083 001	ITRACONAZOLE; SPORANOX				I-104	MAR 29, 1997
18754 001	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
18754 002	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
18754 003	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
19816 001	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	JAN 18, 2000		NCE	NOV 10, 1998
19558 006	LISINAPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 2000	U-77	NCE	APR 12, 1998
20264 001	MEGESTROL ACETATE; MEGACE				NDF	SEP 10, 1997
20343 001	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
20343 002	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
20343 003	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
19297 001	MITOXANTHONE HYDROCHLORIDE; NOVANTHONE	4820738	APR 11, 2006	U-98		
20085 001	NAPHAZOLINE HYDROCHLORIDE; OPCON-A				NC	JUN 08, 1997
20226 001	NAPHAZOLINE HYDROCHLORIDE; NAPHCON-A				NC	JUN 08, 1997
20204 002	NAPROXEN SODIUM; ALEVE				NS	JAN 11, 1997
19660 001	NEDOCROMIL SODIUM; TILADE				NCE	DEC 30, 1997
20165 001	NICOTINE; NICODERM					
20165 002	NICOTINE; NICODERM	4474787	OCT 02, 2006			
		5344656	APR 02, 2008			
		5342623	APR 02, 2008			
		5344656	APR 02, 2008			
		5342623	APR 02, 2008			
		5344656	APR 02, 2008			
		5342623	APR 02, 2008			
>ADD>						
>ADD>						
>ADD>						
>ADD>						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002			I-106 MAY 03, 1997
19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002			I-106 MAY 03, 1997
19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002			I-106 MAY 03, 1997
19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002			I-106 MAY 03, 1997
19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002			I-106 MAY 03, 1997
20103 001	ONDANSETRON HYDROCHLORIDE; ZOFTRAN					I-110 SEP 26, 1997
20103 002	ONDANSETRON HYDROCHLORIDE; ZOFTRAN					I-110 SEP 26, 1997
20262 001	PACLITAXEL; TAXOL					I-105 APR 13, 1997
						D-24 JUN 22, 1997
20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			D-22 APR 15, 1997
						I-111 SEP 21, 1997
20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			D-22 APR 15, 1997
						I-111 SEP 21, 1997
20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			D-22 APR 15, 1997
						I-111 SEP 21, 1997
20031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12		NCE DEC 29, 1997
20031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12		NCE DEC 29, 1997
20031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12		NCE DEC 29, 1997
20031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12		NCE DEC 29, 1997
20031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12		NCE DEC 29, 1997
20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002			NCE DEC 30, 1998
20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002			NCE DEC 30, 1998
20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002			NCE DEC 30, 1998
20237 001	PILOCARPINE HYDROCHLORIDE; SALAGEN					ODE MAR 22, 2001
						NDF MAR 22, 1997
19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004			NCE OCT 31, 1996
19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004			NCE OCT 31, 1996
19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004			NCE OCT 31, 1996
20279 001	PREDNICARBATE; DERMATOP					NDF OCT 29, 1996
19627 001	PROPOFOL; DIPRIVAN					I-99 OCT 26, 1996
20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFDAC/24	4801461	MAY 05, 2004			
		4576604	MAR 18, 2003			
18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4128658	DEC 05, 1995			D-21 FEB 28, 1997
18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4128658	DEC 05, 1995			D-21 FEB 28, 1997
19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4521431	JUN 04, 2002			D-21 FEB 28, 1997

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20236 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008		NCE	FEB 04, 1999
19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19865 005	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
					ODE	OCT 30, 1999
20412 001	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 002	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 003	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 004	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 005	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
40091 001	SULFADIAZINE; SULFADIAZINE				ODE	JUL 29, 2001
17376 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17376 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17377 001	SULFAMETHOXAZOLE; BACTRIM				I-103	JAN 07, 1997
17377 002	SULFAMETHOXAZOLE; BACTRIM DS				I-103	JAN 07, 1997
17560 002	SULFAMETHOXAZOLE; BACTRIM PEDIATRIC				I-103	JAN 07, 1997
17598 001	SULFAMETHOXAZOLE; SEPTRA				I-103	JAN 07, 1997
17598 002	SULFAMETHOXAZOLE; SEPTRA GRAPE				I-103	JAN 07, 1997
20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 29, 2006	U-72	I-103	JAN 07, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD> >ADD> >ADD>	20070 001 TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	20070 002 TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	20070 003 TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
	20070 004 TACRINE HYDROCHLORIDE; COGNEX	4631286	DEC 23, 2003	U-97		
>ADD>	17970 002 TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
>ADD>	18163 003 TEMAZEPAM; RESTORIL	5326758	JUL 09, 2008	U-70		
>ADD>	20192 001 TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73	NCE	DEC 30, 1999
>DLT>	20192 001 TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73	NCE	DEC 30, 1999
	19762 001 TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		4704282	NOV 03, 2004		NDF	OCT 12, 1996
	19762 002 TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		4704282	NOV 03, 2004		NDF	OCT 12, 1996
	20330 001 TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
		4195085	MAR 25, 1997		NP	NOV 04, 1996
	20330 002 TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
		4195085	MAR 25, 1997		NP	NOV 04, 1996
	20326 001 TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	SEP 15, 2004	U-91	ODE	DEC 17, 2000
	19908 001 ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2005	U-74	NCE	DEC 16, 1997
	19908 002 ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2005	U-74	NCE	DEC 16, 1997

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

* 7542

***Charge your order.
It's easy!***



— subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP**, and the monthly Cumulative Supplements, for \$64.00 per year.

The total cost of my order is \$_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents☐ GPO Deposit Account☐ VISA or MasterCard

(Company or personal name)

(Additional address/attention line)

(Street address)

(City, State, ZIP Code)

()
(Daytime phone including area code)

(Purchase Order No.)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To FAX your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.

RM301.45 .A66 1994 Oct Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90036 5210